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ABSTRACT

IMAGE-GUIDED PROTON THERAPY FOR ONLINE DOSE-EVALUATION AND
ADAPTIVE PLANNING

Joey P. Cheung, B.A.
Supervisory Professor: Laurence E. Court, Ph.D.

The main advantage for using protons in radiotherapy is their finite range in patients,
allowing for potential improved sparing of normal tissues. However, this comes at a cost of
increased sensitivity to range uncertainties. Density changes along the beam path will affect
the proton range and the resultant dose distribution, making it difficult to estimate the impact
of visible anatomic changes to the patient dose distribution. In order to better understand the
effect of anatomy change on proton dose, some form of treatment-time verification is
required and methods to correct for observed changes would be beneficial. Therefore, this
project aims to develop image-guidance techniques for proton therapy that incorporates
proton range changes to allow for accurate treatment-time dose verification and corrective
actions to ensure proper dose delivery.
A method for quick estimation of the treatment-time dose based on CT-imaging using
prior dose information was developed and validated. This technique uses changes in
calculated radiological pathlength on CT images to remap prior dose distributions on new
anatomy or new setup position. We assessed the accuracy of this technique compared to full
dose calculation and found the average passing rate of 3D gamma analysis (3% dosevi

difference, 3-mm distance-to-agreement) were 96% and 89% for setup errors and severe
anatomy changes, respectively. The average (maximum) of RMS deviation of the DVHs
under the weekly anatomical change was 0.6% (2.7%) for all structures considered.
Using the quick dose estimation tool, we developed a method to position the patient
based on dose information instead of simply using anatomic information. This would allow
for dose-based optimization to be included in the patient setup process. We found a
statistically significant improvement in target coverage and normal tissue sparing using our
method when compared to anatomy-based setup.
Finally, we assessed a potential method to adapt spot scanning proton treatment plan
beam parameters to account for anatomical changes. This range-adaptive method adjusts the
proton beam directly to match the new range to anatomy in the treatment-time image. Using
this technique, we were able to reduce normal tissue dose but ended up with increased target
heterogeneity and reduced target coverage.
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CHAPTER 1: BACKGROUND
1.1.

Radiation therapy

1.1.1. Brief history of radiation therapy
Radiation therapy has been a major form of curative or palliative cancer treatment for the
past century. Very quickly after the discovery of x-rays by Wilhelm Röntgen in 1895,1
physicians and scientists saw the promise of using ionizing radiation to treat cancer, with the
earliest use of x-rays for cancer treatments dating as early as 1896, just one year after its
discovery. Today, radiation therapy is one of several modern options for cancer treatment
and is often the primary, if not complementary, treatment option for many treatment sites.
Nearly two-thirds of all cancer patients receive radiation therapy at some point in their
illness, with breast, prostate, and lung cancers making up more than half of all radiation
treatments.2, 3

1.1.2. Guiding principles of radiation therapy
Ionizing radiation is effective in killing cancer cells by damaging DNA which leads to cell
death. Tumor control is achieved by delivering enough radiation dose to the target, including
suspected areas of microscopic or subclinical disease and pathways of known spread of
disease including lymphatic drainage systems. However, radiation damage is not only limited
to malignant tissues and any normal tissues within the irradiation volume will be subject to
damage as well. Therefore, efforts made in the past century have largely been to increase the
therapeutic ratio by reducing dose delivered to normal tissues while increasing dose as much
as possible to the target tissues. In addition, a course of radiation therapy is often delivered
over a period of several weeks (in many treatment fractions) in order to allow for damaged
1

normal tissue to heal and to improve tumor cell kill. Tumor cells are typically less efficient in
repairing damage from ionizing radiation compared to normal tissues. Additionally, these
gaps between treatment fractions allows for the tumor cells to reoxygenate and redistribute
within their cell cycles, both of which will increase the sensitivity of tumor cell population to
radiation damage.
The tolerated dose to normal tissues varies greatly depending on the organ-at-risk
involved, which again varies depending on the treatment site. A large effort has been made
recently to provide a comprehensive review of all current knowledge regarding radiation
effects on normal tissue for many important organs involved in radiation therapy treatments
and has been published in a special issue of the International Journal of Radiation
Oncology*Biology*Physics.4

1.2.

Use of proton therapy for improved dose delivery

1.2.1. Brief history of proton therapy
The use of protons for cancer therapy was first proposed by Robert R. Wilson in 1946.5 In
this seminal manuscript, Wilson outlines the properties of high energy proton beams and how
they can be used to treat cancer patients. Figure 1 shows a comparison between the depth
dose distributions for a proton beam and a photon beam. Traditional photon beams deposit
most of their energy near the entrance of the beam within the patient, with an exponential
decrease in dose with increasing depth. This results in a large amount of radiation dose being
delivered to normal tissues both proximal and distal to the target. This is typically overcome
by using many beams to surround the patient in order to spread out dose to normal tissues.
Protons, on the other hand, deposit a low amount of entrance dose and deliver the majority of
2

their dose at the end of range, which is determined by the energy of the proton beam, and
nearly zero dose beyond this range. This depth dose profile is called the Bragg peak, and
potentially allows for improved sparing of normal tissues both proximal and distal to the
target. In order to deliver a uniform dose to a larger volume of tissue, several Bragg peaks
can be pieced together in order to create a spread-out Bragg peak (SOBP), as shown in
Figure 1.

Figure 1: Depth dose curves comparing the difference between a photon and a proton beam.
The 10MV photon beam is shown in black and the pristine Bragg peaks from proton beams
are shown in blue. The resultant spread-out Bragg peak (SOBP) from the summation of
pristine Bragg peaks is shown in red. Reprinted from W. P. Levin, H. Kooy, J. S. Loeffler and
T. F. DeLaney, "Proton beam therapy," Br. J. Cancer 93, 849-854 (2005) with permission
from Macmillan Publishers Ltd on behalf of Cancer Research UK.6

While proton beams have been used to treat cancers for several decades now, only
recently have large patient populations been able to get the treatment due to the opening of
3

several hospital-based proton treatment facilities.7-11 As of the end of 2013, there are 40
proton therapy facilities in operation worldwide, with 13 facilities in the United States and
many more being planned and under construction.12 A total of over 100,000 patients have
been treated with proton therapy since the first treatments in Berkeley, California in 1954.

1.2.2. Potential advantages of proton therapy
Many planning studies have been published showing the improved dose distributions that can
be obtained with proton beams compared to traditional photon beams.13-21 The theoretical
advantages stemming from the finite range of protons can also potentially improve treatment
conformality with the use of fewer beams. Therefore, the integral (total) dose to the patient
will be far lower with protons, which means an overall lower dose to normal tissues. In many
cases, the delivery of radiation therapy to a specific disease site is limited by nearby critical
structures. Therefore, if the dose conformality to the target can be improved, we can
potentially increase the prescription dose delivered to the target in order to increase the
probability of local control. Both of these factors can result in an improvement to enhance the
therapeutic ratio in radiation therapy.

1.2.3. Proton interactions
The dose delivery advantages of proton therapy stem from the fact that they are charged
particles and interact with matter via Coulomb interactions. As a proton traverses through a
medium, it loses energy through successive interactions with atoms in the medium until it
loses all of its initial energy. Most of the energy loss of a proton comes from Coulomb
interactions with atomic electrons. Small deflections of the proton beam that are caused by
4

Coulombic interactions with the atomic nucleus result in a lateral broadening of the beam due
to angular deflection of the protons from their primary trajectory.
Most of the dose deposited by the beam is through the proton interactions with the
outer-shell atomic electrons. This results in a very small loss of energy by the protons
resulting in excitation or ionization of the electrons. The rate of energy loss per unit path
𝑑𝐸

length is defined to be the stopping power �𝑑𝑥 � and is dependent on the particle radiation of
interest and properties of the medium that it traverses through. Due to the small loss of

energy with each interaction for protons, the average path length of a monoenergetic proton
beam can be very closely estimated using the continuous-slowing-down-approximation
(CSDA). This approximation assumes that the rate of energy loss is equal to the total
stopping power and that there is no lateral scattering of the beam. The CSDA range (𝑅𝐶𝑆𝐷𝐴 )

can be calculated by integrating the reciprocal of the total stopping power with respect to
energy:
𝑅𝐶𝑆𝐷𝐴

𝑑𝐸 −1
= � � � 𝑑𝐸
𝑑𝑥
0
𝐸0

(Eq. 1)

where 𝐸0 is the initial kinetic energy of the protons.

The electronic or collisional proton stopping power of a charged particle in a material

can be described using the Bethe formula:
2

𝑑𝐸
4𝜋 𝑛𝑍 2
𝑒2
2𝑚𝑒 𝑐 2 𝛽 2
−
=
∙
∙�
� ∙ �ln �
� − 𝛽2�
𝑑𝑥 𝑚𝑒 𝑐 2 𝛽 2
4𝜋𝜀0
𝐼 ∙ (1 − 𝛽 2 )

(Eq. 2)

where 𝑒 and 𝑚𝑒 are the charge and rest mass of the electron, 𝑐 is the speed of light, 𝜀0 is the
𝑣

vacuum permittivity, 𝛽 is the proton’s velocity over the speed of light 𝛽 = �𝑐 �, 𝑛 is the

electron density of the material, 𝑍 is the atomic number of the material, and 𝐼 is the mean
5

excitation potential of the material. Note that the stopping power is nearly proportional to the
inverse square of the proton velocity. This relationship helps to intuitively describe the shape
of the Bragg peak, since the protons will deposit much higher dose to the material when its
velocity is very low near the end of its range. Calculated stopping powers and range tables
for various materials using the Bethe formula can be found through the National Institute of
Standards and Technology (NIST) PSTAR database.22 In practice, these types of rangeenergy tables along with measured depth doses are used for practical purposes of dose
calculation in proton therapy.
A beam of protons which is initially monoenergetic will end up with some
distribution of energies due to statistical fluctuations in the process of losing energy. This
results from the stochastic nature of the proton interactions causing a fluctuation in the
number of interactions and the energy loss of each interaction. This results in a broadening of
the Bragg peak in the depth direction, also called energy or range straggling.
The scatter of protons is due to elastic Coulomb interactions with target nuclei in the
material. This results in many small angle deflections that serve to broaden the beam (also
called multiple Coulomb scattering), causing a radial spread of the proton beam in the lateral
direction. This can be described using Molière’s theory of multiple scattering, but in practice
we typically use Highland’s Gaussian approximation:
�〈𝜃 2 〉 = 𝑧

14.1 MeV 𝑥
1
𝑥
� �1 + log10 �
𝑝𝑣
𝑋0
9
𝑋0

(Eq. 3)

where 𝑧 is the charge of the particle, 𝑝 and 𝑣 are the momentum and velocity of the particle,
𝑥 is the thickness of the material, and 𝑋0 is the radiation length of the material in which the

particle energy is reduced by a factor of 1/𝑒 due to radiation losses only. This approximation
6

works well for many practical applications and has been shown to agree to better than 5% for
many materials compared to the full theory.23
Protons can also undergo non-elastic nuclear interactions with target nuclei, which
can cause a reduction in the proton fluence with depth and also generate secondary particles
that will deposit dose either locally or at a distance. These secondary particles include
neutrons, protons, deuterons, alpha particles, and recoil nuclei. These particles in general
contribute a very low dose compared to the primary proton dose. However, the higher
relative biological effectiveness of these particles may be a concern. Much attention has
especially been given to secondary neutron dose that is delivered to the patient, but
contributions of secondary particles of other forms are generally more problematic for
particles that are heavier than protons.

1.2.4. Proton delivery techniques
Currently, there are two main delivery methods for proton therapy, passive scattering proton
therapy (PSPT) and active scanning or spot scanning proton therapy (SSPT). Both methods
can be used to deliver proton therapy treatments to a 3-dimensional target volume, but each
has its advantages and disadvantages.
PSPT uses scattering devices, physical range modulators, and physical apertures and
compensators in order to shape the proton beam to deliver dose to the tumor. The scattering
system typically uses double scatterers for large fields in order to spread the beam in the
lateral direction and generate a uniform beam for patient treatment.24 The beam is spread in
the depth direction through the use of a range modulator wheel or a ridge filter which
introduces material of variable thicknesses in the path of the beam to spread out the beam
7

ranges. This allows multiple Bragg peaks of differing energies to be added together to deliver
a nearly uniform dose to the target in the depth direction, namely the SOBP as shown in
Figure 1. The scattering and range modulation systems allow for the treatment of a
volumetric target. In order to shape the beam to conform the dose laterally to the shape of the
target, patient- and field-specific apertures are designed using the treatment planning system
in order to block out the beam to minimize dose to surrounding normal tissues. To shape the
beam to match the distal edge of the target volume, a range compensator is used to correct for
the differences in range needed to reach the distal edge of the target. This delivery method
can result in some drawbacks. Since a single SOBP is used for any given field, normal tissue
proximal to the target volume may receive a high dose. Additionally, since patient-specific
physical apertures and compensators need to be manufactured before treatment delivery,
there is additional overhead needed for each new case as well as if any modifications need to
be made during the course of treatment. Furthermore, the scattering system generates
undesirable secondary neutrons which deposit additional background dose to the patient.
SSPT uses magnets to steer proton pencil beams of different energies and scan the
pencil beam to deliver dose to the tumor.25 This method essentially places Bragg peaks of
different energies throughout the target volume at different depths. The magnetic steering
allows for the dose to be spread in the lateral direction of the beam and is usually performed
through the use of two sets of scanning magnets to scan the beam in orthogonal directions to
each other. The energy can be changed either by the particle accelerator during the beam
acceleration and extraction process (synchrotron), or through the use of energy absorbers
along the beam transport system (cyclotron). Unlike PSPT, SSPT can conform the dose to
both the distal and proximal boundaries of the target because there is no need to deliver only
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a single SOBP width. Optimization techniques in the treatment planning process can be used
to optimize spot positions and parameters to achieve the desired dose distribution. This can
be performed using a single-field optimization (SFO) (also referred to as single field uniform
dose or SFUD) technique in which each field is optimized individually to deliver the full
prescribed dose to the target or using a multi-field optimization (MFO) (also referred to as
intensity-modulated proton therapy or IMPT) technique in which spots from all fields are
optimized simultaneously. The MFO technique can result in each field delivering a nonuniform dose distribution, but the total sum of all fields will yield the desired dose
distribution as determined by the optimization parameters. MFO plans typically result in
patched fields which are much more complex than an SFO plan on a field-by-field basis.
The increased ability for SSPT plans to modulate the proton beam and reduce the
high dose delivered to normal tissues proximal to the target allows SSPT plans to be much
more conformal and flexible than PSPT plans. It also minimizes neutron contamination due
to the absence of high density physical scatterers and blocks in the path of the beam.
However, potential problems exist because the dose is delivered with many different pencil
beams instead of a broad beam like PSPT uses. This makes SSPT much more sensitive to
uncertainties in the planning process and plan delivery as will be discussed in the next
section.

1.2.5. Sources of uncertainty in proton therapy
While one of the main advantages of protons is that they have a finite range and stop within
the patient, this property also makes the delivery of proton therapy especially vulnerable to
uncertainties. The distal falloff of a proton beam is very sharp, with the distal 90% to 10%
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depth dose falloff being on the order of a few millimeters. Therefore, the proper localization
and description of where this distal edge of the beam ends up within the patient is very
important.
Many sources of uncertainty exist in radiation therapy including patient setup error
and immobilization, patient internal motion and anatomic deformation, patient weight loss or
gain, inconsistencies in target delineation, uncertainties in dose calculation algorithms, and
limitations in the mechanics of beam delivery.26-28 While all of these uncertainties exist in
both photon and proton treatments, the impact of these on delivered dose to the patient may
be more substantial for proton treatment.29-31 All of the uncertainties listed can potentially
affect the penetration range of the proton beam inside the patient and therefore affect the
dose distribution that is delivered. An additional source of uncertainty for proton therapy is
the added uncertainty in the conversion of computed tomography (CT) numbers to proton
stopping power ratios (SPR). The SPR is needed in order to properly calculate proton range,
and therefore proton dose, within the patient as will be described in Section 1.8. Since CT
scans are the primary method for incorporating patient specific 3D geometry and organ
information for planning and dose calculation, these CT number-to-SPR uncertainties can
dramatically impact the planned versus actual delivered dose.32
Compared to PSPT, SSPT techniques tend to be more sensitive to uncertainties
because of the method of delivery. While PSPT delivers a broad beam of protons that are
physically spread out, SSPT delivery relies on the appropriate superposition of individual
proton beamlets to deliver the correct dose to the target. Each of these individual beamlets is
potentially subject to different degrees of uncertainties and any deviations from the original
planning conditions can largely affect the shape of the dose distribution. This is especially
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true for MFO plans since deviations from planning conditions can result in the “patchedfields” to deliver unintentionally overlapping or separated patches and result in
heterogeneous total dose distributions. Because of these uncertainties, the evaluation of
robustness of SSPT plans is important to ensure that the proper total dose is being delivered
on a daily basis to the patient.

1.2.6. Proton treatment planning and mitigating uncertainties
While the general concepts in treatment planning for photons apply similarly to protons,
there are several notable factors that need to be kept in mind that make proton therapy
different from traditional photon therapy. These differences stem from the additional
uncertainties that need to be taken into account. ICRU Report 78 presents a comprehensive
outline of the principles of proton therapy and the considerations necessary for planning,
treatment, and dosimetry.33 The proton treatment planning process gets started in the same
manner as photon treatment planning by setting up and acquiring a simulation CT scan of the
patient, often referred to as the planning CT. Image segmentation is performed on these CT
images to define the geometry of the patient and the relation of normal tissue structures to the
treatment target of interest. In defining these structures, certain uncertainties need to be taken
into account. The target volume is usually defined at several different levels as first described
in ICRU Report 50.34 The gross tumor volume (GTV) is tumor that can be clinically
determined through palpation or imaging (anatomical or functional). This can include both
the primary tumor and metastatic involvement. The clinical target volume (CTV) includes
suspected microscopic and subclinical disease. This is usually determined based on
experience and data based on the probability of clinical spread of the disease including the
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disease pathological staging and likely pathways of spread. The internal target volume (ITV)
includes the CTV and uncertainties associated with internal variation of the CTV including
movement and possible deformation of the CTV. The planning target volume (PTV) is a
geometric concept that is used purely for treatment planning and takes into account possible
variations in the beam delivery including patient setup uncertainties and uncertainties and
limitations in the beam delivery. Commonly, the CTV and PTV are derived from the
substructures as a geometric expansion based on measured or estimated setup uncertainties.28
Once the target and normal tissue structures are delineated, the images and segmented
structures can be used to plan the radiation treatment by defining beam parameters such as
beam angles, beam weights, and field sizes. In defining the beam parameters, uncertainties in
treatment planning need to be kept in mind. Typical strategies will place the proton beams in
such a way to avoid aiming directly at normal structures such that the sharp distal dose
gradient stops immediately or close to the surface of a critical structure due to the potential
over-ranging of protons into the normal structure anatomy. Similarly, attempts to avoid using
beams that stop in or near tissues of low density (such as lung tissue) should be made in order
to reduce uncertainties of the proton range due to day-to-day variations that can occur over
the course of treatment. However, the finite range of protons can sometimes allow the
incident fields to be limited to a single side of the patient in order to spare normal tissue far
away from the distal edge of the field. Unlike in photon therapy, the beams do not need to be
distributed around the patient in order to maximally spare normal tissues. Consideration
should also be made to use the shortest possible path to the tumor in order to reduce the
integral dose to the normal tissues that lie proximal to the tumor volume.
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A problem with the current standard treatment planning techniques described above is
that they do not take into account potential morphological changes in the entire patient
anatomy other than the target over the course of treatment. This includes changes in the size
and shape of all organs in the body. This is especially important for proton therapy because
of the sensitivity of the proton beam to materials all along the path of the beam. Therefore, it
is not necessarily enough to simply include the setup and anatomical uncertainties only in
relation to movement of the target volume in the creation of the PTV. Of course, it is not
currently possible to accurately predict the changes that a given patient will undergo during
treatment, which makes it difficult to include this uncertainty in the treatment planning
process which inherently only looks at a single snapshot of the patient at the time of CT
simulation. Therefore, direct methods to evaluate patient anatomical variations are needed.

1.3.

Evidence of variations of internal anatomy in radiation therapy over the course

of treatment
Variations in patient setup and patient anatomy changes that can occur over the course of
treatment can potentially compromise the treatment if not properly accounted or corrected
for. Therefore, an accurate assessment and monitoring of patient changes throughout the
duration of the therapy is an integral component if anatomical changes are expected or
observed.
Traditionally, patients were set up using external markers (usually placed on the
patient’s skin or on the immobilization devices). While this method has been shown to
provide good target coverage using older treatment techniques using larger treatment fields,35
the use of external landmarks to align patients to the radiation fields does not necessarily
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guarantee the correct alignment of internal anatomy for more conformal beam deliveries in
which there is much less room for error. There may be large relative differences between the
patient’s external anatomy compared to internal anatomy between different treatment
deliveries (inter-fraction) and even during a given delivery (intra-fraction) of radiation
therapy. These relative differences can be in position, shape, and volume. Many studies have
investigated the magnitude of tumor and normal tissue inter- and intra-fraction motion and
changes during the course of radiation therapy for many different treatment sites.28, 36-40
Langen and Jones36 have written a comprehensive review of many scientific articles that
quantify inter- and intra-fraction changes. Their review found, for example, that prostate
motion was dominant in the anterior-posterior (AP) and superior-inferior (SI) directions due
to variations in bladder and rectal filling with displacements as large as 20 mm. A similar
study by Sonke et al.39 showed that for non-small cell lung cancer (NSCLC) patients, the
inter-fraction baseline variations are largest in the superior-inferior directions with an
average systematic variation of 3.9 mm.
Morphological changes in tumor shape and volume have been well demonstrated as
well. For example, Barker et al.37 quantified the changes in volume and shape of targets and
normal tissues in head and neck radiation therapy and found that the gross tumor volume
(GTV), which included the primary tumor and involved lymph nodes, decreased
progressively in volume at a median rate of 0.2 cm3 or 1.8% of the original volume per
treatment day, with a median total relative loss of 69.5% by the end of treatment. Sonke et
al.40 compiled a comprehensive review of many studies that have reported tumor and lymph
node regression rates based on volumetric changes during radiation therapy of lung cancer.
Their findings are summarized in Table 1. These studies report regression rates of tumor
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volume ranging from 0.6% to 2.4% per day. A key difference in tumor volume changes in
the lung compared to many other treatment sites is that the reduction in soft tissue tumor
typically gives way to lung tissues with low density. Figure 2 and Figure 3 show examples of
lung tumor morphology changes that can occur in response to treatment for two cases from
our institution. The tumor can shrink radially either isotropically or anisotropically (Figure
2), or can cavitate and develop abnormal textures that will affect the position and shape of
the tumor (Figure 3).

Table 1: Tumor regression rates in volume percentage per day as reported by various studies.
Reprinted from J.-J. Sonke and J. Belderbos, "Adaptive Radiotherapy for Lung Cancer,"
Semin. Radiat. Oncol. 20, 94-106 (2010) with permission from Elsevier.40
Study
Erridge 2003 Edinburgh-NKI/AvL

No.
Patients
25

Modality

Regression
Rate (%/d)
-0.9

EPID

Observations
Microscopic extensions mentioned

Kupelian 2005 M.D. Anderson

10

In room MV-CT

-1.2

Increased dose to PTV and lungs

Siker 2006 Wisconsin

25

MVCT

-2.4

Mixed group, radical, palliative and stereotactic RT

Bosmans 2008 Maastro

23

FDG-PET/CT

-0.39

Lymph node regression only

McDermott 2006 NKI/AvL

1

EPID

-1.5

Increased dose to PTV and lungs

Underberg 2006 VUMC

40

-1.4

Volume. increase 1st and 2nd wk

-1.3

Volume increase 1st and 2nd wk

Britton 2007 M.D. Anderson

8

4D-CT and
conventional CT
In room KV-CT

Woodford 2007 Ontario

17

In room MV-CT

-0.79

Fox 2009 Johns Hopkins

22

MVCT

-1.2

Regression greater (-1.4%) in first 3 wk

Feng 2009 Michigan

14

-1.4

Planning study

Van Zwienen 2008 NKI/AvL

114

Mid-RT FDGPET/CT
In room kVCBCT

-0.6

Frequent anatomical changes occurred

All of these variations in target shape and size are important to monitor and may
result in target underdosage or severe damage to normal tissues if not taken into account
properly during treatment planning or treatment delivery. Additionally, many of the
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described changes are not immediately apparent when observing a patient externally. While
some quantitative measurements such as patient weight, body circumference, or the sourceto-surface distance (SSD) indicator measurements can give hints to patient anatomy change,
most of these metrics fail to detect morphological changes of internal anatomy.

Figure 2: An example of a lung patient with shrinking tumor size due to response to
treatment. On the left is the anatomy from a CT scan before treatment and on the right is the
anatomy from a CT scan after 6 weeks of treatment. The GTV is displayed in red with the
solid lines showing the original GTV and the dotted lines showing the new GTV on the 6th
week of treatment.
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Figure 3: An example of a lung patient with shrinking tumor size due to response to
treatment leading to cavitation of the tumor volume. On the left is the anatomy from a CT
scan before treatment and on the right is the anatomy from a CT scan after 7 weeks of
treatment. The GTV is displayed in red with the solid lines showing the original GTV and the
dotted lines showing the new GTV on the 7th week of treatment.

1.4.

Image-guided radiation therapy for accurate localization in conformal

treatments
Image-guided radiation therapy (IGRT) using in-room imaging devices has allowed for the
assessment and correction of observed anatomical changes over the course of radiation
therapy.41-44 This is performed by capturing images of the internal patient anatomy
immediately before treatment delivery and localizing the target volume. These imaging and
localization capabilities, in conjunction with patient immobilization devices, have been
shown to improve dose delivery by reducing treatment margins and ensuring accurate target
alignment.45-48 Additionally, images from IGRT can be used to track changes of the patient
anatomy over the course of the treatment, including tumor volume changes, normal tissue
changes, and patient external contour changes. This information can then be used to evaluate
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the progress of the treatment on the tumor as well as effects of radiation on normal tissues,
and decisions can also be made on whether adjustments need to take place in order to
accommodate large changes in patient anatomy that could affect the treatment.49-51 This may
lead to the need for an intervention in the middle of a course of treatment to alter the delivery
of the therapy. This can be as simple as adjusting the position of the patient and re-creating
the patient immobilization device, or can be as advanced as completely replanning the
treatment to compensate for the changes. The effort to replan and implement the treatment
during a course of radiation therapy is often called adaptive radiation therapy (ART) and has
been a subject of much research in the past couple of decades.

1.5.

Adaptive radiation therapy

Adaptive radiation therapy was introduced as a way to incorporate patient-specific changes
over the course of treatment to optimize treatment delivery in the face of anatomic changes.49
Figure 4 shows a flow diagram of the adaptive treatment system process as described by
Yan.52 The information gathered for the feedback process can be any number of things
including anatomical, biological, or possibly even tumor genetic variations due to treatment
response. Ultimately, the modification will be made to the dose delivery system, so an
estimation of the delivered treatment dose is an important step in the process as well such
that a decision on the necessary changes can be made.
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Figure 4: Flow chart of adaptive radiation therapy process. Reprinted from D. Yan, "Adaptive
Radiotherapy: Merging Principle Into Clinical Practice," Semin. Radiat. Oncol. 20, 79-83
(2010) with permission from Elsevier.52

Since morphological and physiological changes are difficult to predict and can vary
dramatically between different patients, these evaluations are inherently patient-specific and
the acquisition of patient-specific information is one of the key aspects of adaptive radiation
therapy. As noted, this can be anatomical or biological in nature, and should be evaluated
frequently enough to be able to discover variations that may compromise the treatment as
well as allow time for a response to take place. The utilization of imaging information from
IGRT can be an excellent source of feedback information as it would serve the purpose of
patient localization for setup purposes as well as assess anatomical changes that take place
and can be used for treatment dose reconstruction.53 While biological information of the
treatment response would be immensely beneficial toward improving our ability to tailor
dose prescriptions over time to meet the needs of specific patients and their response, the
clinical application of biologic feedback is in its early stages. Most applications that are in
practice today utilize anatomical information and are typically used to adjust the treatment
plan in order to meet the original clinical goals.
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The clinical implementation of adaptive radiation therapy, however, is a complex
issue due to the large amount of resources needed to monitor treatment progress and to
implement the treatment modifications. With current technology and systems in place, these
modifications usually require a long sequence of events to execute, including time-intensive
treatment replanning, quality assurance, and scheduling. This can be a burden for the
workload of a radiation oncology clinic and efforts to reduce the time for any of these steps
and to streamline the workflow are necessary before wide-ranging implementation can take
place.

1.6.

Need for treatment time verification and adaptive planning for proton therapy

As discussed earlier, a major problem with proton therapy is its sensitivity to range
uncertainties.30, 31, 54-56 This is especially the case if there are large anatomical changes that
occur during treatment. For example, if the patient loses weight or the tumor shrinks, the
proton beam will traverse through less tissue before reaching the target, resulting in the
proton beam overshooting the target and overdosing distal normal tissues. Alternatively, if
the patient gains weight or the tumor grows due to cancer progression, the beam may
encounter a higher density of material, resulting in the proton beam undershooting the target
and underdosing the tumor. Any change in tissue density along the path of the proton beam
will affect the proton penetration range. Therefore, in proton therapy it is not only important
for the target anatomy to be in the same position, but all surrounding anatomy needs to
consistently be in the same position as the original plan as well. Consequently, there needs to
be some way to track and monitor any potential changes in anatomy throughout the course of
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treatment in order to ensure proper dose delivery to the patient and to adapt the proton
therapy treatment if necessary.
A review of our institution’s numbers for proton therapy patients suggests this need
for treatment evaluation. Figure 5 shows the total number of new patients treated and the
total number of patients who received some sort of adaptive planning intervention at our
institution for select services in the years 2011-2013 (Matt B. Palmer, MBA, CMD, e-mail
communication, February 2014). Over these three years, a grand total of 3,033 new patients
from these services were treated, of which 199 (7%) of them required an adaptive
intervention. In terms of the absolute number of patients, thoracic cancer patients received
the most adaptive plans, followed by CNS and pediatric cancer patients, and then head and
neck patients. Figure 6 shows a graph of the percentage of the total patients who received an
adaptive intervention each year separated by treatment site. Other than gynecological (GYN)
patients who had a high percentage due to the small number of cases treated, head and neck
and thoracic cancer patients lead with the most percentage of patients within their group
requiring adaptive planning. The relative percentage of these patients requiring adaptive
planning has been fairly steady over the past three years, suggesting similar needs for
adaptive planning within this population of patients.
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Figure 5: Patient statistics for new start and adaptive cases at the MD Anderson Cancer
Center Proton Therapy Center (PTC) for select services in the years 2011-2013. On the left is
the total number of new patients treated and on the right is the total number of patients who
received some sort of adaptive planning intervention during that time period.
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Figure 6: Percentage of the total patients who received an adaptive intervention each year
from 2011-2013 separated by treatment site.
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1.7.

Proposed proton dose and range verification methods

Several methods of proton dose and range verification have been proposed over the past few
years using different modalities. One potential method investigated by several groups is the
use of positron emission tomography (PET) for imaging activated positron emitting isotopes
in tissues.57-60 Similarly, others have investigated the imaging of prompt gamma ray
emissions from similarly activated isotopes in tissues after proton irradiation.61, 62 Both of
these methods have the potential advantage of providing real-time or near real-time
verification of dose actually deposited within the patient, but would require the
implementation of additional imaging device technologies in the treatment room.
Gensheimer et al. has noticed changes in MRI tissue response after proton radiation exposure
that can be used to identify tissues that received dose.63 However, the extent of these changes
seen in MR images will be site dependent and it is difficult to quantify the dose actually
delivered to tissues based on MR images alone. Proton “range probes” and proton
radiographs or proton CTs have also been proposed to verify in-vivo proton ranges.64-66
These methods use a high energy proton beam that penetrates through the patient to be
detected by a detector. The residual range of the proton beam at the detector can then be
compared to a pre-calculated or pre-measured residual range at the time of treatment
planning to estimate the range variations. If rotational projection images are acquired, a CT
reconstruction can be obtained as well. However, these techniques are still in development
and image reconstruction and detection methods are currently being explored.
Another method that can be used to evaluate and monitor proton dose and range
variation is with CT imaging. As noted earlier, CT imaging is the foundation for treatment
planning which includes dose calculation and evaluation. Additionally, CT-based imaging is
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currently used for photon treatment setup for in-room IGRT. Since CT images are currently
used for treatment planning in proton therapy, treatment time evaluation with the same
modality would allow for an intuitive comparison to the desired doses from the original
treatment plan, and would allow for direct replanning on the treatment day CT for adaptive
radiation therapy, if necessary.

1.8.

Proton range calculation from CT imaging

In order to use CT imaging for proton dose and range verification, we need to understand
how to acquire proton range information from the patient images. Proton ranges are
commonly described in terms of equivalent ranges in water, often labelled as waterequivalent path length (WEPL) or water-equivalent thickness (WET). This allows for a
common comparison of ranges between different types of materials and also allows for an
easy way to measure and describe ranges of proton beams through different materials.67 In
order to calculate the WEPL, the linear SPR of the given material to that of water is needed.
Information about the SPR for tissues within a patient can be obtained from a CT image by
using a CT number-to-SPR calibration curve. An example of the calibration curve used for a
clinical CT scanner at the MD Anderson Proton Therapy Center is shown in Figure 7. This
calibration curve can be obtained through different means, but the most commonly used
technique for radiation therapy planning is the stoichiometric method that was originally
proposed by Schneider et al.68 This method uses both measured Hounsfield units (HU) of
tissue substitutes and the chemical composition of tissues in order to predict the HU for
human tissues in the images.
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With the calibration curve, we can determine the SPR of tissues within each voxel of
the CT scan. Therefore, given the path of a proton beam through the CT scan (as can be
determined by the beam angle and isocenter if the beam), the WEPL can be calculated by
taking the cumulative SPR through the voxels along the path of the proton beam. Therefore,
with information obtained from a treatment-time CT image along with the beam parameters
that are determined for a patient’s treatment, we can calculate the expected penetration depth
and position of a proton beam within the patient.
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Figure 7: Example of the CT Number-to-SPR calibration curve used for a clinical CT scanner
at the MD Anderson Proton Therapy Center
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1.9.

Conceptual shift in utilizing IGRT for protons

The sensitivity of proton beams to all tissues along the beam path makes it difficult to
estimate the impact of visible anatomic changes in a CT image to the dose distribution within
the patient. This complicates the idea of image guidance for proton therapy because visible
alignment of the target soft tissue or bony anatomy may not be enough to ensure dose
coverage.31, 69-71 This is inherently a big conceptual change compared to current utilization of
IGRT techniques in photon therapy.72 Figure 8 shows the differences between the effects of
weekly anatomical change in a lung patient on the dose from a photon intensity-modulated
radiation therapy (IMRT) plan and a proton PSPT plan. The doses from each weekly CT scan
for this patient, after taking into account patient rigid alignment to bony anatomy, are
overlaid on top of the original planning CT. Notice that even though the patient positioning
was corrected for using rigid alignment, the doses from the proton plan (particularly in the
distal edge of each of the beams) vary considerably whereas the doses from the photon plan
remain fairly static. Therefore, the underlying assumption in photon radiotherapy that the
target can be shifted as a rigid object in an invariant (or static) dose cloud73 is not necessarily
valid in proton therapy. The proton dose distribution is intrinsically non-static due to the
finite range of the proton beam which depends heavily on the density of the material along its
beam path. In addition to the anatomical changes, if the patient is rigidly shifted around, the
shape of the dose distribution can vary as well depending on the heterogeneities within the
path of the beam.
a) Proton PSPT

b) Photon IMRT
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Figure 8: Example of dose variation due to anatomy change between photon and proton beam
therapy. Doses due to weekly anatomical motion change overlaid over the original planning
CT scan for (left) photon IMRT, and (right) proton PSPT plans. Notice the large amount of
dose distribution changes (the blurring of the isodose lines) seen in the distal edges of the
proton beam plan compared to the relatively small changes seen in the photon IMRT plan.

In order to fully utilize the daily anatomical information from these volumetric
images, we need to take into account the physical dose deposition properties of protons to
predict where the dose will go in the patient. Ideally, full dose recalculations with a dose
calculation algorithm would be utilized on a daily basis to check the dose distribution on the
daily anatomy and to assess different setup positions (i.e. different couch shifts). However,
dose calculation engines are currently too slow to use for online dose assessment. Therefore,
a quick method of estimating the daily proton range or proton dose distribution is necessary
in order to perform online patient verification. If this range or dose information is available,
corrections can be performed to adjust for deficiencies in dose delivery.
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CHAPTER 2: HYPOTHESIS AND SPECIFIC AIMS
2.1.

Goals for this project

The main objective of this work is to investigate the potential use of online 3D volumetric
imaging with conventional kilovoltage CT to improve our ability to deliver the correct
radiation dose to cancer patients treated with proton therapy. One goal is to transfer the
ideology of 3D IGRT from the realm of photons to protons. However, with the unique
properties of proton therapy, the ideology of image guidance will need to be modified. As
with any image-guidance procedure, this requires the development of a method of detection
of anatomy change from imaging information, and a correction intervention strategy.
Specifically for this project, this involves the design of a method for treatment day dose
verification, and then performing corrective strategies of isocenter shifts or adaptive
planning. These objectives will be explored in the three specific aims as described below. All
of the techniques developed in this work are aimed to be feasibly used as an online process.

2.2.

Overall hypothesis

A radiological pathlength calculation algorithm based on CT imaging can be used for:
1) online proton beam treatment day verification and isocenter adjustment, and
2) an online adaptive range adjustment technique based on pathlength correction
in order to maintain target coverage and reduce normal tissue dose.
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2.3.

Specific Aims

Specific Aim 1: To develop an online proton dose verification tool based on daily CT
imaging to assess the effect of anatomy change on the proton beam and validate its ability to
evaluate target coverage and dose distribution.

Working Hypothesis: The online range corrected dose approximation tool can estimate the
dose distribution based on the new patient anatomy to an accuracy given by a gamma index
(3%/3mm) ≥ 85% when compared to full dose recalculation.

In this aim, we will implement a radiological pathlength calculation algorithm based on CT
imaging to map out treatment day range changes and to use this information to create a fast
range compensated dose approximation method to estimate the treatment day dose. This
technique should be relatively quick and would enable us to perform an online visualization
of the impact of daily anatomical changes on proton range and dose. This fast dose
approximation will also allow for the use of dose information in the IGRT process and can be
used as a tool for quick dose verification in order to determine if adaptive planning is
necessary.

Specific Aim 2: To devise a novel patient setup correction method for proton therapy based
on dosimetric indices and to assess its ability to maintain target coverage and improve normal
tissue sparing.
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Working Hypothesis: Using the dosimetric alignment method based on the fast range
compensated dose approximation technique (from specific aim 1) will result in a statistically
significant reduction in normal tissue dose compared to anatomical alignment.

The second aim is to develop an approach to correct for patient anatomy changes by simply
performing a rigid couch shift. This is analogous to using the anatomical information in
IGRT for target localization and patient setup. However, anatomical alignment is not
necessarily the optimal patient position, and range or dose information needs to be taken into
account when evaluating patient setup. By developing a methodology for incorporating daily
range variations into the online dose verification process, we can use this information to
determine the best possible patient setup without modification of beam parameters.

Specific Aim 3: To develop an online range compensation beam adjustment technique to
correct for range variations due to anatomical changes while preserving target coverage in
proton therapy.

Working Hypothesis: The online range-adaptive technique based on pathlength correction
can maintain the original target dose coverage (V95%) to within 5% while significantly
reducing normal tissue dose compared to non-adaptive treatments for patients with large
anatomic change.

The goal of the third aim is to determine if an online range-adaptive or range compensation
technique can be used for online adaptive radiation therapy. This range-adaptive technique
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will be used to correct for changes in proton range due to anatomy changes and relative shifts
in heterogeneities. We propose that, based on the results of the radiological pathlength
calculation, proton range perturbations due to anatomy change relative to the nominal plan
can be compensated for directly and used to correct the proton beam for day-to-day anatomy
changes in order to match the original planned isodose lines without a full reoptimization.
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CHAPTER 3: SPECIFIC AIM I - DEVELOPMENT OF CT-BASED FAST PROTON
RANGE AND DOSE VERIFICATION TOOLS
(This chapter is based upon P. C. Park, J. Cheung, X. R. Zhu, N. Sahoo, L. Court and L.
Dong, "Fast range-corrected proton dose approximation method using prior dose
distribution," Phys. Med. Biol. 57, 3555 (2012) as published by the author of this dissertation
and the right to include this work in the author’s own research dissertation is exercised as
established under the transfer of copyright agreement with IOP Publishing Ltd.)74

3.1.

Introduction

3.1.1. Evaluation of setup and anatomical uncertainties for proton therapy
Understanding and inclusion of various effects of uncertainties on a planned dose distribution
are a vital part of the treatment delivery evaluation process. The treatment planning dose
distribution is only a snapshot of the dose based on the assumed setting at the time of
calculation and is therefore subject to variations under different conditions, including patient
setup and anatomical changes. This is particularly true for proton therapy because proton
beam ranges depend heavily on the tissue density along its path. Any changes that can
influence the given WEPL of the proton beam can potentially result in differences between
the delivered and planned dose distributions. This includes anatomical changes over the
course of treatment, as well as slight shifts in the patient position or isocenter.
Uncertainties in setup and range can cause differences between the value of WEPL
from the treatment plan and actual WEPL at the time of beam delivery.30, 31, 37, 75 Also, both
intra- and inter-fractional anatomical changes have been shown to cause significant changes
in the planned dose distribution.76-78 In addition, trends through the weeks of treatments can
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further change the dose distributions compared to the original treatment plan, such as patient
weight loss and tumor volume change in response to radiation 79. For conventional photon
therapy such as 3-dimensional conformal radiotherapy or IMRT, geometrically expanded
volumes such as PTV or planning organ-at-risk volume (PRV) are routinely used for robust
treatment planning and evaluation.33, 34 A photon treatment plan that is designed to deliver
sufficient dose to the PTV can be thought of as a robust plan as long as the CTV resides
within the PTV volume. In terms of treatment evaluation, dose coverage to PTV and PRV
can be thought of as the worst case scenario for the CTV and organ-at-risk (OAR) volumes,
respectively. However, this is based on the assumption that the dose distribution is static and
that the calculated dose distribution under the nominal (reference) setting will not change
significantly with respect to the changes in patient surface contour, tissue density, and organ
motion. In this situation, the photon dose distribution does not need to be re-calculated
because it is virtually independent of patient’s anatomy. This so called static dose distribution
assumption holds true for conventional photon therapy to a certain extent.73 However,
numerous authors have discussed the fallacy of using the static dose distribution assumption
in proton therapy primarily due to the fact that proton ranges are sensitive to the change in
tissue density or WEPL.80, 81 This effect can, again, be seen in Figure 8 which shows the
photon IMRT dose with minimal blurring while the distal end of the proton dose is blurred
noticeably due to changes in patient anatomy.
Ideally, in order to gauge the robustness of a given proton treatment plan under
various situations, multiple dose calculations are required in order to simulate different
possible changes. Recently, researchers have developed methods which incorporate multiple
dose distributions under different setup and range errors to derive dose volume histograms
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(DVHs) or its derivatives in order to evaluate treatment robustness.82-84 Similarly, if the
anatomy changes over the course of treatment, the proton dose distribution will need to be
recalculated on the new treatment-time image in order to get an accurate assessment of the
dose delivered. However, due to the computational cost of calculating proton dose
distributions under various circumstances, the clinical feasibility of robust evaluation and
optimization are difficult to implement. Additionally, if online dose calculation is needed for
patient setup, a full dose recalculation may be too time-intensive if multiple calculations are
required for dose reassessment after changing patient position.

3.1.2. Using range deviations for dose approximation
In this aim, we describe a fast range-corrected dose approximation method based on a
composite version of the methods described by Unkelbach et al.69 The major difference in
our method compared to theirs is that we use the dose distribution from the nominal setting to
‘predict’ the new dose under a small perturbation in WEPL without requiring the detailed
knowledge of the individual dose contributions from pre-calculated virtual pencil beams.
This is motivated by the heuristic observation that perturbation of the WEPL along the beam
path pulls the dose profile proximally or distally from the nominal setting without
significantly changing its overall shape. Figure 9 illustrates an example of dose profile
variation after a single insertion of a high-density object in the beam path. Therefore, we can
estimate the dose delivered by assessing the change in ranges to different locations in the
image. One way of visualizing this is by generating a contour map of range-equivalent
isodose line compared to a reference image. In essence, this would give an approximation of
where the isodose that was intended to cover the target ended up on treatment day anatomy.
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This would allow for a very quick estimation of the coverage provided on the treatment day
target. An example of this is shown in Figure 10 for a pelvic phantom. Even better, the entire
new dose distribution can be estimated by simply shifting the dose profiles based on an “isoWEPL” along the beam direction. An example of this estimated dose distribution for the
same pelvic phantom compared to the treatment planning system dose calculation is shown
in Figure 11. This equivalent-WEPL based dose correction strategy can be very quick and
can reduce both computational time and computer memory requirements compared to full
dose recalculation. We will benchmark the fast range-corrected dose approximation method
against the full dose calculation using a commercial treatment planning system that is based
on the 3D pencil beam convolution method.85, 86 Furthermore, we will assess the ability of the
dose approximation method to estimate DVH curves.

3.2.

Methods and Materials

In principle, the dose to a point can be calculated by summing up all contributions of doses
from individual beamlets. Here, we will not pursue the dose calculation of each individual
beamlet; rather, we make the assumption that the scattered dose from small changes in the
patient’s anatomy will remain constant and the dose effect is only caused by the change in
the cumulative WEPL at each voxel along the beam path. This WEPL can be calculated from
CT images as was described in Section 1.8. Taking advantage of the full dose calculation at
the nominal position, we can derive the new dose distribution by shifting dose along the
beam path based on the equivalent WEPL from the original plan. One can think of this as a
mapping process where a previously known dose distribution is re-organized to give a new
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dose distribution. This requires that a single full dose calculation is performed using the
planning CT images under the nominal setting.

Figure 9: Example of the dose profile variation due to high density material. An oval shaped
heterogeneity was inserted in the beam path to simulate anatomical changes. The density of
the object varied from 0 HU to 1200 HU in increments of 400 HU. The line dose profiles
beyond the start location of heterogeneity (indicated by the arrow) are pulled proximally
towards the source as the density of the hetergeneity increases according to the effective
change in the WEPL while the rest of the profile proximal to the heterogeneity remains
approximately the same.
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Figure 10: An example of estimating the range variation due to treatment day anatomy
change using our radiological pathlength algorithm to calculate a range-equivalent isodose
line. A treatment plan was generated for the original anatomy (left) and recalculated on the
altered anatomy (right) in which a bone-like object is placed in the beam path. The range
perturbation is calculated using the WEPL for the 100% isodose line (isodose-RE) and
matches fairly well with the new isodose line from full dose calculation in our treatment
planning system.

Figure 11: The dose distributions from the full dose recalculation from our treatment
planning system (left) versus the range-compensated dose approximation (right) for the
pelvic phantom with bone-like material inserted into the path of the beam.

In this study, we used our clinically commissioned proton treatment planning system
(Eclipse™ version 8.9, Varian Medical Systems, Inc., Palo Alto, CA, USA). This dose
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distribution is referred as the nominal dose distribution (𝐷) while the dose under the testing
situation is referred as realized dose distribution (𝑑). 𝐷 will be used as a template when we

approximate 𝑑 under the influence of both position and anatomical change. For convenience,
we used a beam’s eye view (BEV) coordinate and the z-axis as the depth along the beam’s
axis. A point dose at an arbitrary coordinate of (𝑥, 𝑦, 𝑧), with (0,0,0) being defined at the

isocenter, under nominal setting can be written as 𝐷𝑥,𝑦,𝑧 . The realized dose to that point can

be written as a function of the patient shift error (∆𝑥, ∆𝑦, ∆𝑧) and change in physical depth
(𝑧 ′ ), giving 𝑑𝑥,𝑦,𝑧 (∆𝑥, ∆𝑦, ∆𝑧, 𝑧 ′ ). It should be noted that 𝑧 ′ is a fundamentally different

quantity than ∆𝑧: ∆𝑧 is the magnitude of patient position change in physical space whereas

𝑧 ′ is the location in depth under nominal setting which corresponds to the same WEPL for the
depth at 𝑧 under the realized or testing setting.

For the case of the static dose distribution (i.e. for photon beam), we can immediately

approximate the realized dose to a point as follows:
𝑑𝑥,𝑦,𝑧 (∆𝑥, ∆𝑦, ∆𝑧) = 𝐷𝑥+∆𝑥,𝑦+∆𝑦,𝑧+∆𝑧

(Eq. 4)

In this formulation, one can see that for static dose distribution, the realized dose can
be approximated by simply moving the entire dose cloud to align with the patient anatomy in
its new position. To account for the variant dose distribution, we assume that the perturbation
in WEPL moves point doses in physical space according to their WEPL values in the original
plan.
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3.2.1. Approximation under setup error or patient shift
If setup error occurs or if a dose calculation is needed after a patient shift, there will be a
change in WEPL due to the misaligned tissue density along the plane that is perpendicular to
the beam’s axis. This will lead to a difference in WEPL between the line segments tracing
different locations in space. Therefore, in order to approximate the realized dose at a point,
we need to account for the difference in WEPL between the line segments tracing different
locations in space by
𝑑𝑥,𝑦,𝑧 (∆𝑥, ∆𝑦, 𝑧 ′ ) = 𝐷𝑥+∆𝑥,𝑦+∆𝑦,𝑧 ′ × 𝐼𝑁𝑉(𝑧, 𝑧 ′ ),

where 𝑧 ′ is given by the following line integral relation
𝑧

𝑧′

� 𝑟𝑠𝑝(𝑥, 𝑦, 𝑧)𝑑𝑧 = � 𝑟𝑠𝑝(𝑥 + ∆𝑥, 𝑦 + ∆𝑦, 𝑧)𝑑𝑧
𝑠

𝑠

(Eq. 5)

(Eq. 6)

The function 𝑟𝑠𝑝(𝑥, 𝑦, 𝑧) is the relative stopping power ratio from the given CT data and 𝑠 is
the effective source position. Simply put, (Eq. 5) approximates the realized point dose by

shifting the ray line geometrically (in the BEV coordinate) while adjusting the longitudinal
dose profile given by that shifted ray line according to the effective change WEPL from (Eq.
𝑧 ′ +𝑉𝑆𝐴𝐷

2

6). In (Eq. 5), 𝐼𝑁𝑉(𝑧, 𝑧 ′ ) = � 𝑧+𝑉𝑆𝐴𝐷 � is the inverse square factor to compensate for the loss

in protons in a divergent beam with the effective source-to-axis distance (VSAD). Here, the
effect of a patient shift along the direction of the beam axis (∆𝑧) is ignored (except for the

inverse square factor) because it is equivalent to adding an air gap between the source to the
patient body surface which adds a negligible change in WEPL.
In general, 𝑧 ′ can only be determined by solving (Eq. 6) iteratively, making it the most

time consuming step for this method. The computational time can be decreased by saving the
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line integral values at different depth with the corresponding 𝐷 values in computer memory

and referencing them as a look up table for later use.

3.2.2. Approximation under anatomical change
For anatomical deformation without considering the setup error (assuming the images have
been registered together), we can approximate the realized dose as
𝑑𝑥,𝑦,𝑧 (𝑧′) = 𝐷𝑥,𝑦,𝑧 ′ × 𝐼𝑁𝑉(𝑧, 𝑧 ′ ),

(Eq. 7)

where 𝑧′ is given by the limit of the following integrals
𝑧

𝑧′

� 𝑟𝑠𝑝(𝑥, 𝑦, 𝑧)𝑑𝑧 = � 𝑟𝑠𝑝𝑁𝑒𝑤 (𝑥, 𝑦, 𝑧)𝑑𝑧
𝑠

𝑠

(Eq. 8)

In this case, the realized dose will be a function of the effective change in WEPL caused by
the anatomical deformation, which can be tracked using the new images (i.e. treatment-time
CT images), which gives the function 𝑟𝑠𝑝𝑁𝑒𝑤 . For the above formula, the location of the line
being integrated is identical since no setup error is assumed but 𝑟𝑠𝑝𝑁𝑒𝑤 (𝑥, 𝑦, 𝑧) is used on

the right side of (Eq. 8) to account for the anatomical deformation given by the new images.
Finally, the approximation method under setup error and anatomical deformation can be
combined to give a general formulation
𝑑𝑥,𝑦,𝑧 (∆𝑥, ∆𝑦, 𝑧′) = 𝐷𝑥+∆𝑥,𝑦+∆𝑦,𝑧′ × 𝐼𝑁𝑉(𝑧, 𝑧 ′ ),

where again, 𝑧′ is given by the limit of the following integrals
𝑧

𝑧′

∫𝑠 𝑟𝑠𝑝(𝑥, 𝑦, 𝑧)𝑑𝑧 = ∫𝑠 𝑟𝑠𝑝𝑁𝑒𝑤 (𝑥 + ∆𝑥, 𝑦 + ∆𝑦, 𝑧)𝑑𝑧.
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(Eq. 9)

(Eq. 10)

This range corrected dose approximation method can be summarized as a simple dose
mapping algorithm which maps previously calculated dose distributions onto a new one
based on the following steps:
Step 1. Calculate the WEPL to a point along the beam path under the nominal setting.
Step 2. Translate beam’s isocenter according to the position change or introduce new
CT images.
Step 3. Calculate WEPL along the corresponding line segment and locate the
physical point along the depth which has the same WEPL as calculated in Step 1.
Step 4. Correct for inverse square factor based on the original physical location found
in Step 3.
Step 5. Repeat steps 1-4 for all points in the image.

3.2.3. Validation for patient cases
In order to validate our dose approximation method, we compared the dose distributions
calculated using a static dose approximation, our proposed range-corrected dose
approximation, and a full 3D pencil beam convolution method from our clinical treatment
planning system (TPS). All dose calculations were performed using a dose grid resolution
of 2 × 2 × 2.5 𝑚𝑚3. First, a lung cancer patient was selected. The patient received 4-

dimensional computed tomography (4DCT) scans for treatment planning and weekly over
the course of treatment with a 1mm pixel size and 2.5mm slice thickness over the first 6
weeks (denoted week0 to week6) of treatments. To simplify intra-fractional dose calculation,
we used the average image from the 4DCT data sets for each week. Treatment plan under

nominal setting and all consequent dose calculations were done on these averaged CT data
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sets following the clinical protocol used at our institution.87 The PTV was generated by a
uniform expansion of the CTV with 5mm margins. This margin size was deliberately chosen
to push the limit of the plan’s robustness to CTV coverage when we simulate position shifts
up to 8mm. All the volumes of interest were contoured by a physician on the planning CT
and were deformed to weekly CT data sets using an in-house developed deformable image
registration software.88, 89 The nominal dose was calculated using the planning CT data set
with no assumed setup error via the spot scanning beam delivery method with single-field
optimization.7 The position shifts were then simulated by shifting the planning CT images
along the Anterior-Posterior direction ±8mm in 2mm intervals. At each interval, doses were
calculated using all three different methods: static dose approximation, our proposed rangecorrected dose approximation, and a full recalculation with the TPS. For the weekly CT data
sets, doses were calculated using all three different methods after manual alignment of
beam’s isocenter based on the bony anatomy to separate the effect of setup error.
Similarly, we validated the proposed method on a prostate and a head & neck (HN)
patient case with inter-fractional anatomic changes to show the applicability of the proposed
method to these sites as well. The prostate case was chosen due to a change in the femur
position on the day of treatment. The HN case was chosen because of a substantial change in
the nasal air cavity in the beam path on week 6 of treatment, which was partially due to a
head rotation and tissue/fluid variation in the nasal cavity. We used a 270° beam angle for the
prostate case, and a 0° beam angle for the HN case.
The overall accuracy of both approximation methods were quantified through the use
of a 3D gamma analysis tool developed in-house.90 Our gamma analysis was performed
using a common 3% dose-difference and 3mm distance-to-distance agreement criteria (3%,
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3mm). We also performed the gamma analysis using other criteria, (1%, 3mm) and (3%,
4mm), due to possible interest for different levels of accuracy for different applications. All
gamma analyses were performed on the dose distribution greater than 10% of the
prescription dose. In order to quantify the accuracy of the cDVHs derived using the rangecorrected method, cDVHs were subtracted from the corresponding cDVHs derived using full
dose calculation (The difference is denoted as ∆cDVH).
3.3.

Results

3.3.1. Dose distribution comparison and 3D gamma analysis
For all cases, the amount of dose variations gradually increased as position shift increased
from 0mm to 8mm in both directions (perpendicular to the beam line). For the lung case, the
amount of dose variation was gradually increased from week0 to week6 while both prostate
and HN cases showed no obvious increment in dose variation over the weeks. Table 2 shows
% volume change of the tumor in the entire breathing cycle (i.e. integrated gross tumor
volume and clinical target volume (IGTV and ICTV), and GTV-50 and CTV-50, the volumes
for the exhale phase of the breathing cycle) for the lung patient over the course of treatment.
The largest variation of the planned dose distribution amongst all of the simulations was
observed when we recalculated dose using the 6th treatment week’s CT images for both lung
and HN cases and the 1st week CT images for the prostate case.
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Table 2: The measured volume change of the target volumes of interest observed in the
weekly CT images for the lung case in Specific Aim 1. The structures were contoured on the
planning CT and deformed to the weekly CT images using in-house deformable image
registration software. For the selected patient case, a reduction of 41% of the gross tumor
volume (GTV-T50 and IGTV) and 21% of the clinical target volume (CTV-T50 and ICTV)
was observed.

Visually noticeable change in dose distribution was observed when position changes
and anatomical deformations were introduced. Figure 12 (a) and (b) compares planned dose
distribution and the realized dose distribution using full dose calculation. It shows, as a result
of weight loss and tumor shrinkage, the proton beam penetrating deeper in to the patient,
delivering a significant dose to the contralateral lung. The original spatial dose distribution
given by the static approximation (Figure 12 (c)) fails to adjust for such a change and thereby
significantly underestimates the dose to contralateral lung. However, the realized dose
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distribution computed using the range-corrected method (Figure 12 (d)) is able to estimate
the change in depth penetration of the proton beam with a reasonable accuracy.

Figure 12: An example of the resultant dose distributions for the lung case for dose
approximation. (a) The full dose (TPS) calculation on the lung planning CT (planned dose
distribution). (b) The full dose (TPS) calculation on the lung week6 CT (realized dose
distribution). (c) The static dose approximation on the lung week6 CT. (d) The range
corrected dose approximation on the lung week6 CT.
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Figure 13: An example of the dose difference between different proton dose calculation
methods. The percent dose difference map on the lung week6 CT between dose distribution
using full calculation and dose distribution using (a) static dose approximation, (b) range
corrected approximation, and (c) the percentage dose difference histograms for the two
difference maps. Red dashed line in the histogram is derived from (a) while blue solid line is
derived from (b).

Figure 13 shows percentage dose difference maps of the dose distributions between
the full dose recalculation and the static dose approximation, and the full dose and the range
corrected dose approximation. Note that an over estimation near the patient skin surface and
an under estimation in the contralateral lung region was apparent from the static dose
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approximation method while a significant improvement was observed when using the rangecorrected approximation method.
The results of the gamma analyses are presented in Table 3, Table 4, and Table 5. The
lowest passing rate was observed at the limit of our simulation ranges (8mm position changes
and lung 6th week). Under the (3%, 3mm) criteria, the range-corrected method achieved a
93% passing rate for an 8mm position change while the static dose approximation method
achieved only an 81% passing rate. For the weekly CT simulation, the range-corrected
method achieved an 86% passing rate for the 6th week CT while the static dose
approximation method achieved only 36% passing rate. For the other gamma index criteria,
(1%, 3mm) and (3%, 4mm), the general results were similar. They are presented here out of
interest for possible other applications in which different passing criteria would be of interest.
For the (3%, 3mm) criteria, the worst passing rate found for the 3D gamma analysis
of the prostate case was 89% and 83% for the range corrected and the static approximation
methods, respectively. Similarly, the worst passing rate found for the HN case showed 84%
and 70% passing rates for range corrected approximation and static approximation methods,
respectively. Figure 14 and Figure 15 show the comparisons graphically. The original plan
calculated for the anatomy in the treatment planning CT image is shown in the left panel for
each case; the dose distributions in the changed anatomy (due to inter-fractional variations)
are calculated by the commercial TPS (Eclipse; middle column) and the dose approximation
method (right panel), respectively. It can be seen that the range-corrected dose approximation
method did a reasonable job overall. Most differences are seen in regions with sharp change
in WEPL. In these regions, more accurate modeling of lateral scatter appears to be important.
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Table 3: The result of the (3%, 3mm) 3D gamma analysis on both the ranged-corrected
approximation and static dose approximation with respect to the full dose (TPS) calculation
under position change and weekly CT simulations. For the sake of simplicity, for both
prostate and HN cases, only the worst passing rate observed during weekly simulation is
shown (week1 for prostate and week6 for HN).

Lung
Position change
(mm)
-8
-6
-4
-2
0
2
4
6
8

3D Gamma (% Passing)
(3%, 3mm)
(3%, 3mm)
Range corrected
94%
95%
97%
98%
100%
98%
96%
95%
93%

Static
81%
87%
93%
98%
100%
98%
93%
88%
83%

3D Gamma (% Passing)
(3%, 3mm)
(3%, 3mm)
Site (Week)
Lung (0)
Lung (1)
Lung (2)
Lung (3)
Lung (4)
Lung (5)
Lung (6)
Prostate (1)
HN (6)
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Range corrected
100%
89%
89%
91%
89%
86%
86%
89%
84%

Static
100%
75%
74%
66%
54%
43%
36%
83%
70%

Table 4: The result of the (1%, 3mm) 3D gamma analysis on both the ranged-corrected
approximation and static dose approximation with respect to the full dose (TPS) calculation
under position change and weekly CT simulations. For the sake of simplicity, for both
prostate and HN cases, only the worst passing rate observed during weekly simulation is
shown (week1 for prostate and week6 for HN).

Lung
Position change
(mm)
-8
-6
-4
-2
0
2
4
6
8

3D Gamma (% Passing)
(1%, 3mm)
(1%, 3mm)
Range corrected
57%
66%
77%
90%
100%
91%
78%
67%
59%

Static
74%
78%
83%
89%
100%
90%
84%
78%
74%

3D Gamma (% Passing)
(1%, 3mm)
(1%, 3mm)
Site (Week)
Lung (0)
Lung (1)
Lung (2)
Lung (3)
Lung (4)
Lung (5)
Lung (6)
Prostate (1)
HN (6)
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Range corrected
100%
64%
61%
67%
64%
55%
59%
58%
60%

Static
100%
44%
44%
39%
28%
22%
17%
49%
12%

Table 5: The result of the (3%, 4mm) 3D gamma analysis on both the ranged-corrected
approximation and static dose approximation with respect to the full dose (TPS) calculation
under position change and weekly CT simulations. For the sake of simplicity, for both
prostate and HN cases, only the worst passing rate observed during weekly simulation is
shown (week1 for prostate and week6 for HN).

Lung
Position change
(mm)
-8
-6
-4
-2
0
2
4
6
8

3D Gamma (% Passing)
(3%, 4mm)
(3%, 4mm)
Range corrected
98%
98%
99%
100%
100%
100%
99%
98%
97%

Static
87%
92%
96%
99%
100%
100%
97%
93%
89%

3D Gamma (% Passing)
(3%, 4mm)
(3%, 4mm)
Site (Week)
Lung (0)
Lung (1)
Lung (2)
Lung (3)
Lung (4)
Lung (5)
Lung (6)
Prostate (1)
HN (6)
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Range corrected
100%
94%
94%
96%
95%
92%
93%
94%
93%

Static
100%
82%
83%
74%
63%
51%
45%
89%
83%

Figure 14: A comparison of the dose calculation results in the presence of inter-fraction
anatomical changes for the prostate case. The dose distributions for the changed anatomy
calculated by the commercial treatment planning system (Eclipse, Varian Medical Systems)
are shown in the middle column, and the dose distributions calculated by the range-corrected
dose approximate method are shown to the right, respectively.

Figure 15: A comparison of the dose calculation results in the presence of inter-fraction
anatomical changes for the head-and-neck case. The dose distributions for the changed
anatomy calculated by the commercial treatment planning system (Eclipse, Varian Medical
Systems) are shown in the middle column, and the dose distributions calculated by the rangecorrected dose approximate method are shown to the right, respectively.
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3.3.2. DVH comparisons
The change in the planned dose distribution due to both setup and anatomical deformation
resulted in variation of cDVHs derived from realized dose distributions. Figure 16 compares
the DVH-bands (the area enclosed by the envelope of the cDVHs) of various structures using
full dose calculation and different dose approximation methods. Figure 17 shows a mesh plot
of the differences for visualization of several of the structures that we observed. The overall
shape of the DVH-bands derived using range-corrected method closely resembled the DVHbands derived using the full dose calculation, while the DVH-bands derived using static
method mostly under estimated the thickness of the bands for the CTV and other structures
(except for the esophagus under setup position change simulation). In the case of weekly
simulation, the static dose approximation completely failed to account for the decrease in
dose to the target volume and increase in dose to the left lung and esophagus. Table 6 lists
the RMS and the maximum difference from the ∆cDVH. Overall, the RMS deviation and

maximum difference were larger for the CTV and esophagus than for other structures due to
their small volume size and their position near the high dose gradient. For the lung case, the
largest of the RMS deviation found were within 2% for both the setup and weekly
simulation. The largest of the maximum differences were found to be within 4% and 8% for
setup and weekly simulation, respectively. The average of the maximum differences over all

simulations was found to be 1.5% and 2.6% for setup and weekly simulation, respectively for
the lung case.
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Figure 16: DVH comparisons between different dose calculation methods for a lung patient.
The cDVHs of the ITV (red), involved lung (dark blue), contralateral lung (light blue), and
esophagus (black) derived from realized dose distributions under various setup position
changes (top row) and weekly imaging (bottom row) using static approximation (a, d), full
dose calculation (b, e), and range-corrected approximation methods (c, f). The thicker lines
indicate original DVHs derived from the planned dose distribution.
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Figure 17: A mesh plot of the differences in DVH between the range-corrected
approximation method and the full dose (TPS) calculation. Results are shown for the ITV
(red), involved lung (dark blue), contralateral lung (light blue), and esophagus (green). The
top row shows the differences for the setup position change cases, and the bottom row shows
the differences for the weekly lung cases.
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Table 6: The root mean square (RMS) deviations between the cumulative DVHs derived
using a full dose (TPS) calculation and range-corrected dose approximation method under
various simulations. The first two tables are from setup position changes (in the anteriorposterior direction) and weekly simulations of lung patient. For the sake of simplicity, for
both prostate and HN cases, only the worst passing rate observed during weekly simulation is
shown (week1 for prostate and week6 for HN).
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The range-corrected dose approximation method was implemented using MATLAB
(MathWorks Inc., Natick, MA) on a computer with an Intel(R) Core™2 Duo CPU of 3.00
GHz clock speed and 3GB of RAM. The typical calculation is less than one second for each
beam, which is approximately 50 times faster than the full dose calculation method using the
commercial TPS.

3.4.

Discussion

The main purpose of the range-corrected dose approximation method is to compute proton
dose under various circumstances for evaluating patient setup or for evaluating a given
treatment plan’s robustness and for potential incorporation into robust optimization
techniques. Because such tasks may require hundreds of dose calculations, accuracy of the
computed dose may be sacrificed over the computational efficiency. It can be understood that
the approximated dose may not reflect the accuracy requirement for the final dose calculation
in a clinical plan. Nevertheless, the approximated dose can be used for gauging a plan’s
sensitivity to setup and range error, for intermediate dose calculations during plan
optimization, or for online assessment of major dosimetric impacts. For this reason, it may be
sufficient for such important applications.
Our choice to use the 3D gamma analysis was to demonstrate that the approximated
dose distribution is spatially comparable to the full dose calculation. The overall accuracy in
terms of percentage passing rate presented in Table 3 depends heavily on the choice of
passing criteria. In this work, we selected a 3% dose difference and 3mm distance-toagreement criteria and found that the average passing rate was 93% and 89% for setup errors
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and anatomical changes, respectively. The question of what criteria to be used and what the
minimum passing rate should be considered acceptable would depend on the nature of
applications. In this study, we used CT slice spacing of 2.5mm. When performing ray-tracing
in co-planar beam directions, the aliasing effect could affect the accuracy of dose mapping
using our method. This is especially true when using a 3-mm distance-to-agreement criterion,
which is very close to the CT resolution (2.5 mm) in the slice thickness direction. In the
future, we could resample between adjacent CT slices to minimize the aliasing effect.
Aside from the actual dose distribution itself, we also measured the accuracy of
cDVHs derived using the approximated dose. This is highly relevant to the application of the
proposed method since when evaluating the robustness of a plan or the dose on the day of
treatment, it is necessary to summarize the multiple 3D dose distributions into statistical
information such as DVH-bands. Previously, Cho et al.73 discussed the clinical
recommendations on accuracy of DVH curves. Based on the assumption that the point dose
accuracy of 2-4% is clinically tolerable, the RMS of the difference in relative dose between
two cDVH should be less than 1-2%. This RMS criterion measures overall accuracy of the
cDVH curve and permits certain dose bins to deviate more than the 2%, while still being
clinically acceptable. From our experience, this can happen if the OAR is small or is situated
near the beam penumbra and high dose gradient. For the proposed method, Table 6 shows
that RMS deviation is well within 2% for all simulations except for the right-optic nerve and
left parotid from H&N case.
It should be noted that the lung case chosen in this study was a challenging case for
dose calculation. The lateral beam arrangement also maximized the dosimetric effect of
anatomical changes. We selected this case to test if our dose approximation method can do
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well in the presence of significant anatomical changes. We also challenged the proposed
method using a prostate and a HN case. Both cases had a relatively large change in patient’s
anatomy that would affect the proton beam delivery for these sites. The results were similar
to the ones found for the lung case (See Table 3 and Table 6).
In our current implementation, we only used a single CPU for dose calculation, which
already can achieve the calculation speed of around one second. Further reduction of
computation time can be realized because the proposed method allows for parallel calculation
of using independent beamlets or ray-tracing lines. It can be expected that the speed of
computation can benefit from the implementation of multi-processor and multi-core CPU
methods or even GPU based computation method because our proposed method uses a lookup table approach. Sometimes, additional speed increase is possible if we are only interested
in a sub-volume of anatomy. We can selectively choose the dose calculation region of a
specific organ to further speed up the DVH calculation if necessary.
One of the limitations of the proposed method is that it does not consider change in
scattered dose separately from the primary dose when mapping the pre-calculated nominal
dose. The errors resulting from this simplification will be more pronounced for greater
displacement of setup error and near regions with a sharp gradient of tissue density change
lateral to the beam direction. The pencil-beam based dose calculation algorithm used in
Eclipse treatment planning system is also not ideal in modeling the lateral scatter under
complex geometries or heterogeneities. A Monte Carlo based dose calculation method would
produce more accurate assessment of the proposed method.

58

3.5.

Conclusion

In order to expedite robust plan evaluation, a simple and fast proton dose approximation
method was introduced. The proposed method takes advantage of the pre-calculated planned
dose distribution when approximating a new dose distribution by correcting the difference in
proton range under setup error or anatomical deformation given by the new set of CT images.
The accuracy of the range-corrected method was shown to be superior to the static dose
approximation method. The main dosimetric differences between the range-corrected method
and the clinically used full dose calculation method are in small regions where a shape
change in the WEPL exists. These regions are typically narrow and near the edge of a major
WEPL change for which the lateral scatter modeling becomes important. In this study the
differences between these dose distributions were quantified for selected patient cases using
both a 3D gamma analysis and cDVH comparison. Our results show that the static dose
approximation is inadequate to approximate dose for proton beam plans while the proposed
range-corrected dose approximation method can be used effectively to approximate dose
under various setup errors and anatomical deformations. The proposed method could be used
for robust evaluation, robust optimization, and online treatment assessment.
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CHAPTER 4: SPECIFIC AIM II - A DOSE-BASED ALIGNMENT PATIENT SETUP
TECHNIQUE USING PRE-TREATMENT CT IMAGES
(This chapter is based upon J. P. Cheung, P. C. Park, L. E. Court, X. R. Zhu, R. J.
Kudchadker, S. J. Frank and L. Dong, "A novel dose-based positioning method for CT
image-guided proton therapy," Med. Phys. 40, 051714-051719 (2013) as published by the
author of this dissertation and the right to include this work in the author’s own research
dissertation is exercised as established under the transfer of copyright agreement with
AAPM.)71

4.1.

Introduction

Proton therapy has the potential for creating conformal dose distributions and delivering
lower doses to normal tissues than traditional photon therapy due to its ability to modulate
range.15, 17 However, this advantage also complicates treatment delivery because changes in
patient anatomy affect the proton beam’s range within the body.69, 91 This sensitivity to range
uncertainties can cause deviations from the planned dose distribution when significant
changes in patient anatomy occur during multi-fractionated radiation therapy.
While image-guidance has allowed for us to position the patient accurately using
anatomic landmarks, the resultant dose distribution in the patient is not always apparent and
methodologies to obtain this are still being developed.53, 92 While the static dose cloud
approximation is valid for photon beams in most cases, the same is not true for proton
beams73, 74: as tissue density and thickness change along the proton beam path, so can the
resultant dose distribution (potentially to a substantial degree). In theory, a perfect geometrybased target alignment may not guarantee a good dosimetric coverage for the target in proton
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therapy because variations of tissue density outside the target may impact the proton dose
distribution (depending on the geometry and heterogeneity of the irradiated volume). Current
methodologies to mitigate dose variations caused by interfractional patient setup errors
include compensator expansion (smearing)93 and the inclusion of margins.94 However, these
methods are limited to mitigating only rigid shifts of patient and do not address anatomical
changes that can result in tissue shrinkage, deformations, misalignment of anatomical
structures outside the target, patient weight loss, etc. Therefore, anatomy-based shift will not
be ideal to correct all of these daily variations. Adaptive planning may be required to
compensate for these changes,76, 95 but adaptive planning requires more resources, such as
segmentation of structures, replanning, quality assurance testing, etc., that may not be
practical to apply in every fraction. Different patient setup positions will result in different
perturbations to the dose delivered.70, 96 The magnitude of dose perturbations due to
anatomical changes is difficult to assess by looking at anatomy alone, and therefore a timely
assessment of the dose distribution for the patient under a given setup condition is desirable.
These complexities imply that a dosimetric index to assess target and normal tissue dose
under the specific delivery geometry may be necessary for proper treatment-day alignment.
In other words, image-guidance in proton therapy may differ from traditional photon therapy
in that anatomical alignment based on visual imaging information may not always be
adequate, and adjustments may need to be made based on dosimetric assessment due to
proton range variations caused by anatomic changes.
We hypothesized that dosimetric based objectives are needed to fully optimize the
patient setup position in proton therapy. Instead of replanning, our corrective action uses a
simple isocenter shift to correct patient setup, similar to image-guided radiation therapy setup
61

but using calculated dose information instead of anatomic information. This will make it
more practical to apply in routine treatment. Furthermore, by optimizing patient setup using a
dose-based alignment method, we can determine whether adaptive planning is necessary to
achieve the clinical goal when a simple realignment of the isocenter is inadequate.

4.2.

Methods and Materials

4.2.1. Patient data set
We selected 15 lung cancer patients treated at our institution between October 2009 and
February 2011 that had clinically approved proton plans with only 2 or 3 coplanar beams for
each treatment fraction. This data was chosen in order to simulate the differences between
anatomy-based and dose-based alignment. Lung patients were chosen because the proton
dose distribution is more sensitive to anatomy change due to large changes in tumor-to-lung
boundaries, making them suitable for the purpose of this study. Each passively scattered
proton beam was designed to cover the entire planning target volume. Table 7 shows the
patients’ tumor characteristics for this study. Several of the patients were replanned over the
course of treatment to mitigate anatomical changes seen in imaging. While some of the
patients received adaptive replans during the course of treatment due to large anatomical
changes (as indicated in Table 7), we only used the original treatment plan for our study to
observe the impact of these changes to the treatment and assess the ability of our new method
to correct for these changes. The patients selected for this study were a subset of protocol
patients who were enrolled in a randomized clinical trial to compare proton therapy and
photon IMRT for lung cancer.97 The treatment plans were created with the following
parameters: PTV D99% ≥ 95% of the prescribed dose; total lung V20Gy ≤ 37%; total mean lung
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dose (MLD) ≤ 22Gy; maximum spinal cord dose ≤ 45Gy; and minimizing dose to the
esophagus V65Gy and V45Gy and heart V60Gy and V30Gy. The gross tumor volume (GTV) at
individual phases from the 4DCT was used to create the internal gross tumor volume
(iGTV)98, which was expanded by 8mm and manually edited by the treating physician to
become internal target volume (ITV). The PTV was created with a 5mm uniform expansion
of the ITV. A proximal and distal margin of 3.5% of the total water equivalent path length
plus 3mm was added to the ITV along the central beam path to account for range
uncertainties, and a lateral expansion of 1.0-1.5cm to the aperture for the ITV in each beam
angle was introduced to account for uncertainty in setup position. An expansion of the
compensator included to compensate for misregistration of heterogeneities.93 More details of
the treatment planning parameters can be found elsewhere.87 Figure 18 shows the planned
dose distribution on the treatment planning CT scan for patient 1 of this study. Patients were
set up with kV orthogonal planar imaging and immobilized using a wing board with vacuum
bag and head holder, and knee and foot cradles.99
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Table 7: Patient and tumor characteristics for Specific Aim 2.

Figure 18: Planned dose distribution and beam angles for patient 1 for Specific Aim 2 study.
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Each of these protocol patients had weekly 4DCT for evaluation during the course of
treatment. These repeat CT scans were used to simulate treatment-time images for patient
alignment. All of these patients were treated in free-breathing condition. We used the timeaveraged 4DCT, which was generated by averaging the CT numbers for 10 respiratory
phases at each voxel location. To simplify further, we examined the CT image from only the
patients’ last available weekly CT scans since those scans were expected to have the largest
anatomical changes compared with the original treatment planning CT scans. Some of the
treatment beams may pass through the CT couch, therefore the CT data representing the
imaging couch were replaced with a digital treatment couch using in-house software to
properly account for beams that intersected the treatment couch.100 Contours from the
original planning CT image were propagated to the treatment-time image using in-house
deformable image registration software88, 101, 102 to delineate the patient anatomy at the time
of treatment for DVH calculations. The algorithm was assessed for use in automatic contour
propagation for repeat CT and 4DCT imaging and found that interfraction accuracy of 0.4
mm mean absolute surface-to-surface distance and intrafraction accuracy of >98% volume
overlap was achievable when compared to the physician-modified contours.101

4.2.2. Anatomy-based alignment
All weekly images were registered to the planning CT image using bony structures in the
vertebrae nearest the target to simulate the image guidance technique used at most proton
centers today: kilovoltage orthogonal projection imaging, which can detect bony anatomy
sufficiently for alignment purposes. This baseline alignment based on bony anatomy was
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used as the reference to compare with the proposed dose-based alignment and will be
referred to as anatomy-based alignment through the rest of this manuscript. We also obtained
alignment positions for the iGTV to check whether our dose-based alignment ended up
clustering close to iGTV alignment. These alignments were performed using in-house image
registration software with a region-of-interest based alignment method, which is able to
achieve sub-millimeter registration accuracy with disagreements to human adjustments of
greater than 3 mm less than 2% of the time.102, 103

4.2.3. Dose-based alignment
For the dose-based alignment, dose metrics need to be extracted from the new treatment day
CT image. In order to do this, we need to calculate the dose distributions for a number of
couch setup positions with relative patient shifts in the x-, y-, and z- directions from the
baseline anatomical alignment. This will allow for the assessment of the impact of the dose
delivered for various setup positions in order to find the optimal setup for the patient to
achieve the desired target coverage while minimizing dose to normal tissues. Once an
optimal shift is established, these coordinate shifts can be applied to the treatment couch to
position the patient in the final optimal treatment position.
Again, a full calculation of dose distributions for every possible setup position would
require a significant amount of time and/or computational resources that would not be
practical for online clinical use. To remedy this problem, we used the fast dose
approximation method74 from Specific Aim 1 to calculate the dose to organs for different
patient positions. We showed in the previous section that this calculation method can
sufficiently account for changes in tissue density accompanying various setup and anatomical
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changes for the purposes of optimization or quick dose assessment. Using this method, we
recalculated the dose from each beam for multiple rigid isocenter shifts (no rotations) of up
to 8 mm in each direction (x, y, and z) in 2 mm increments (based on the dose calculation
grid size), resulting in 729 dose calculations per beam angle. The 8 mm search limit was
selected because our lateral circular margins for aperture expansion in lung proton therapy
are typically 1cm. This allows us to have some room to shift the patient around with the
target still confined within the aperture in the high dose region. This search space may need
to be defined differently for different applications to suit the treatment plan design.
To further minimize the computation time required, we calculated doses only for the
voxels within the volumes of interest, which included the target volume and the ipsilateral
lung in this study. DVHs were obtained from each shift, and were used to determine the
optimal alignment. We used the target coverage constraint that 99% of the ITV would
receive at least 95% of the prescribed dose (D99% ≥ 95%), and optimized the normal tissue
dose by minimizing the mean dose to the ipsilateral lung. If the target coverage constraint
was not met, the shift that maximized target coverage was defined as the optimal alignment.
The optimality of the target coverage and organ-at-risk doses can be visualized in a solution
space plot with non-dominated solutions mapped out on a Pareto frontier, which is the set of
solutions in which no one parameter can be made better without making the other parameter
worse (e.g. lung dose cannot be decreased without reducing target coverage).
Figure 19 shows the general workflow required for dose-based alignment. For this
study, the dose-based alignment algorithm was implemented using MATLAB (version 7.12.0
[R2011a]; The MathWorks Inc., Natick, MA) as a plugin to CERR (Computational
Environment for Radiotherapy Research, Washington University in St. Louis, St. Louis,
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MO)104 and performed on an Intel Xeon X5680 3.33-GHz central processing unit (Santa
Clara, CA). After we obtained the optimal setup position using each dose-based alignment
methods, we imported the final isocenter information into the Eclipse proton treatment
planning system (Varian Medical Systems, Inc., Palo Alto, CA) for final dose calculations, so
we could compare the dose-based alignment with the anatomy-based alignment.

Figure 19: Workflow diagram for the dose-based alignment method compared to the current
IGRT workflow.

4.2.4. Statistical analysis
The statistical analysis focused on two sets of comparisons between the optimization
methods: coverage of the target, and dose to normal tissue. For the first of these, we used the
exact McNemar test to determine whether the methods significantly differed in meeting the
target coverage constraint. For the second, we compared the changes in mean dose to the
ipsilateral lung using a 2-tailed paired t test with a 95% confidence interval. We performed
our statistical analysis using GraphPad Prism (version 5.00 for Windows; GraphPad
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Software, San Diego, CA) and a p-value less than 0.05 was considered statistically
significant.

4.3.

Results

Seven of the 15 cases did not meet the target coverage constraint of D99% ≥ 95% of the
prescribed dose to the internal target volume when using the anatomy-based alignment. For
five of these patients, the target D99% dropped below 90% and two of these dropped below
66%. When applying isocenter corrections using the dose-based alignment shifts, we were
able to recover the target dose for all 7 of these patients (p=0.0156) and meet the target
coverage constraint. Table 8 lists the target (ITV) coverage and mean ipsilateral lung dose
statistics for all 15 patients.
The dose-based method resulted in mean ipsilateral lung doses that were lower by an
average of 2.74% of the prescribed dose, or 2.03 Gy for a prescribed dose of 74 Gy (p =
0.0147). The maximum decrease in mean ipsilateral lung dose was 11.0% of the prescribed
dose. If considering only the 8 cases in which the target constraint was met for both the
anatomy-based and the dose-based alignment methods, the average decrease in mean
ipsilateral lung dose was 4.5% (p = 0.0083), with decreases occurring in all but 1 case
(patient 5).
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Table 8: Target (ITV) coverage requirement and mean ipsilateral lung dose for patients
assessed for dose-based alignment.

Patient
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Target (ITV) D99%*†
AnatomyDose-based
based
alignment
alignment
99.4%
96.8%
95.3%
100.5%
80.5%*
95.8%
93.8%*
97.0%
98.2%
98.9%
96.9%
96.6%
100.4%
96.2%
97.7%
97.2%
101.1%
98.8%
87.5%*
96.7%
80.2%*
95.6%
94.4%*
96.7%
65.7%*
95.7%
57.2%*
95.7%
100.4%
95.8%
*

Mean ipsilateral lung dose
(% of prescribed dose)
AnatomyDose-based
based
alignment
alignment
45.3
38.4
51.5
40.5
40.3
34.0
61.8
60.2
21.0
21.7
54.1
52.5
42.9
38.3
53.3
49.0
38.3
35.0
39.2
42.2
58.9
61.7
47.4
46.3
76.1
73.1
45.2
46.2
51.0
46.1

did not meet target constraint

Figure 20 shows a scatter plot and histogram of the vector magnitude differences of
the isocenter shifts comparing the dose-based alignment to bony and internal gross tumor
volume (iGTV) anatomy-based alignments, demonstrating that the dose-based alignment was
not the same as either bony or iGTV anatomy-based alignments, and that the dose-based
shifts did not cluster together toward any other observable anatomy.
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Figure 20: Scatter plot and histogram of vector magnitude differences of the isocenter shifts
comparing the dose-based alignments with the bony alignment and iGTV alignment.

Figure 21 shows DVHs for the target and the ipsilateral lung for patient 13, with
separate results shown for the anatomy-based alignment and the dose-based alignment
methods. In this case, the results of anatomy-based alignment did not meet our target
coverage constraint while the results of the dose-based alignment methods met the constraint.
In addition, after applying our optimized dose-based alignment shift, we reduced the mean
dose to the ipsilateral lung by 2.3 Gy (3% of the prescription dose). Figure 22 shows the
optimization tradeoff between target coverage (D99%) and mean ipsilateral lung dose for all
dose-based shifts evaluated in the search space. The Pareto frontier, which shows the nondominating solutions for both the target coverage and normal tissue sparing, is shown as well
as the dose-based shifts which satisfy the target coverage constraint and minimized normal
tissue dose (green star). The dose distribution images overlaid on the CT for the same patient
(patient 13) are shown in Figure 23. When looking at the dose clouds, it is apparent that a
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much larger volume in the anatomy-based bony-alignment is underdosed when compared to
the dose-based alignment. Interestingly, a lot of the underdosed regions fall near the center of
the ITV and not out near the edges, likely due to overshooting of the posterior oblique beam,
causing an underdosage in the proximal portion of the resulting spread out Bragg peak. For
this patient, the D99% improved from 65.7% up to 95.7% using our dose-based alignment.

Figure 21: Example DVHs for the dose-based alignment method versus the anatomical
alignment method. DVHs are shown for the target (left) and ipsilateral lung (right) for patient
13. The anatomy-based and dose-based alignment DVHs are shown by the gray and blue
dashed lines, respectively. The DVH bands show the extent of all of the dose calculations in
the search space, with the gray band corresponding to the calculated DVHs that did not meet
the target coverage constraint and the red and cyan bands showing the DVHs that did meet
the constraint.
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Figure 22: An objective plot of the solution space of mean ipsilateral lung dose versus target
D99% for the dose-based alignment method. Calculated solutions are shown in the blue dots,
with the doses for anatomy-based and optimized single-isocenter dose-based alignments
shown in the red and green stars, respectively. The target coverage constraint is shown by the
green dashed line (above the line is meeting the constraint), and the Pareto frontier (nondominated solutions) is shown by the solid red lines.

73

Figure 23: Dose distributions for Patient 13 for the a) plan and the last weekly CT based on
b) bony-alignment, and c) dose-alignment. The dose clouds between 95% to 110%
prescription dose levels for the bony-alignment and dose-alignment methods are also
presented in axial, coronal, sagittal viewing planes to illustrate target coverage and locations
of underdosage.

4.4.

Discussion

Image-guidance represents the latest development in radiation therapy. Although volumetric
(CT-based) image guidance is popular in photon therapy, its deployment and full usage in
proton therapy are still in the early stage. Due to the unique characteristics of proton dose
distributions, image guidance alone may only solve a part of setup problems. It is important
to note that proton compensators are designed with smearing margins in order to be robust to
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setup and motion errors, but do not account for anatomical changes during the course of
treatment. Therefore, while the patient may be set up correctly based on anatomic landmarks,
this may not be the most ideal setup based on the treatment time anatomy. Because proton
dose distribution changes with changes in anatomy, the use of dosimetric objectives to set up
a patient is perhaps more appropriate for proton therapy. Since our treatment goal is always
dosimetric in that we desire the target to receive the treatment prescription, a dose-based
assessment is closer to our eventual goal, which makes our dose-based alignment viable in
daily management of setup and range uncertainties. The method is based on the imperfect
correction by the traditional anatomy/target alignment method. We assume the compensator
and aperture will remain the same as in the original plan. Correction to the compensator and
aperture will require daily adaptive planning, which is not feasible in current technology or
workflow. Our method is an intermediate step towards adaptive radiotherapy. It uses a simple
isocenter shift, but the shift is based on dose calculation of the original plan applied to the
daily anatomy. Therefore, it may be easier to deploy in clinical practice.
Our analysis is based on CT imaging acquired using the same scanner that is used for
CT simulation. Full implementation of this method would require in-room or remote
volumetric imaging resources with availability during pre-treatment setup, a robust and
accurate deformable image registration tool for propagation of contours, and available
software at the treatment workstation for performing the dose-based alignment and
subsequent review. During the treatment planning and verification stage, the physician would
need to decide on organs-at-risk to monitor for dose-based alignment and action levels could
be established to determine when a physician review is necessary or a full adaptive
replanning process needs to be triggered. Clinical application of our technique would likely
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utilize either a CT-on-rails system, remote patient positioning system105, or in-gantry conebeam CT (CBCT) imaging. If a separate CT scanner is used, effort would need to be made to
ensure that the CT calibration curve for conversion from CT number to relative linear
stopping power is correct for the verification scanner. A CBCT system can be used if the CT
numbers in the CBCT can be accurately corrected to match with the simulation CT or
accurately calibrated for conversion to relative linear stopping power for proton dose
calculation. A possible method for correcting these images for this purpose is to use
deformable image registration to convert the CBCT to a “virtual CT” with CT number
corrections, as described by Peroni et al.106 and others107. These corrections would need to be
accurate enough to be used in treatment planning to be feasible for use in this application.
As we saw from Table 8, the D99% target dose coverage dropped down to as low as
65.7% and 57.2% for two of the patients in our study when using bony anatomy to set up the
patient. This is a very large dose decrease to the target resulting from the changes in
heterogeneities in the patient which were not accounted for in the planning process. These
types of errors could not be directly assessed if no dose information or periodic assessment of
anatomy change was included. Fortunately, both of these patients received adaptive replans
during the course of treatment due to the establishment of a weekly evaluation of the proton
lung protocol patients. However, our results also indicate that a simple isocenter shift based
on calculated dose distributions using treatment time CT images could be enough to correct
for this drop in target dose coverage. This would allow us to correct it to an acceptable level
without full-fledged adaptive replanning which will involve more resources. In addition, the
dose-guided alignment could be used to indicate if a full adaptive replan is necessary based
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on the dosimetric analysis if the target coverage or normal tissue dose cannot be corrected to
an acceptable level.
The accuracy of the algorithms employed for the dose-based alignment method is
important to consider when defining action levels for correction or adaptive planning. The
fast dose approximation method employed here74 was shown in the previous chapter to be
accurate for DVH calculations with an average and maximum root-mean-square deviation in
DVH of 0.50% (average of 0.25% for the ipsilateral lung), which is sufficiently accurate for
assessment of MLD. With smaller organs-at-risk that are close to high gradients, this
accuracy will decrease, but even for the esophagus which is relatively small and was located
right next to the high dose gradient, we found that the average RMS deviation in DVH was
only 1.2% (maximum for any one case was 3.4% for shifts of up to 8mm).
Our study and technique is only focused on correcting for interfractional anatomic
changes, and currently does not address intrafractional changes due to patient movement or
physiologic motion such as patient breathing. Any compensation for motion management is
considered to have been accounted for in the treatment planning process. Additionally, while
we examined lung patients for our study, this technique is not limited to lung treatments and
could be applied to any anatomical site.
It is important to note that anatomy-based alignment may be sufficient in cases where
anatomical changes are minimal. However, we have also shown that for cases in which the
target coverage is acceptable even with anatomy-based alignment, dose-based alignment
reduced dose to the normal tissue of the ipsilateral lung except in 1 case. This patient had the
smallest tumor and the treatment therefore was the most sensitive to small differences in
dose, especially near high-gradient regions. However, the resultant root mean square (and
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maximum) difference in DVH between the dose-based and anatomy-based alignment
methods for this case was 1.0% (2.1%), which is within the uncertainty of the fast dose
approximation method74 and perhaps could be due to the search resolution used in this study
(2 mm). While the average decrease in mean ipsilateral lung dose of 2.74% (~2 Gy) for all
patients is seemingly small, this change is an appreciable dose reduction in the case of the
ipsilateral lung due to its large absolute volume. The recent QUANTEC review for dose
effects in the lung found that there was no suggested absolute safe MLD below which there is
no pneumonitis, and reduction of risk for radiation pneumonitis is suggested to decrease by
about 8% for a 2 Gy reduction based on a logistic regression fitted to multi-institutional
data.108
For this study, we evaluated only the dose to the target and one organ-at-risk
(ipsilateral lung) to show that the methodology works. In general, any number of organs-atrisk can and should be incorporated into the objective function, and the optimal dose to
normal tissues will be a tradeoff, in which case the optimal dose to normal tissues will
necessarily require prioritizing/balancing the doses to each organ-at-risk. There are many
ways to implement multicriteria optimization. In optimizing multiple criteria for dose-based
alignment, a dose-volume–based single objective function similar to that implemented in
treatment planning can be used. For each case, the user can select the objectives to reflect the
best clinical scenario. For example, the dose to the spinal cord is generally an important
objective that needs to be monitored. For patient 7, we noticed that the maximum dose to the
spinal cord dose was above 45 Gy for both the anatomic and dose-based alignment setup
positions. By adding equally weighted constraints to minimize the maximum dose to the
spinal cord maximum dose and the mean dose to the esophagus, we were able to reduce the
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maximum dose to the spinal cord by 18 Gy to below 45 Gy and mean dose to the esophagus
by 7 Gy but raising the mean dose to the ipsilateral lung by 6 Gy. Depending on whether this
increase dose to the lung is acceptable or not, decisions need to be made to reweight the
optimization parameters to achieve the best clinical solution for the specific needs of the
patient. The ultimate choice of the specific organs and weights to be included in the objective
function should be left to the physician and depend on patient-specific acceptable target and
normal tissue dose compromises. Depending on the optimization parameters selected, the
dose-based alignment may potentially be the same as the anatomy-based alignment; however,
unless dose-based evaluation is performed, there is no way to validate if the anatomy-based
alignment is indeed the best solution. We developed a graphical user interface to allow users
to input specific DVH parameters to optimize the patient alignment and assess the costbenefit for competing objectives (Figure 24).
Currently, we are using an exhaustive approach with discrete intervals since it allows
us to demonstrate the concept because our current resources are powerful enough that we can
calculate doses in about 7–15 min depending on the number of beams in the plan and the
volume of the organs of interest. Ideally, total time for setup and imaging evaluation should
take about 5-10 minutes or less. A refined optimization algorithm for determining search
directions might improve the calculation speed. Computing time could also be greatly
reduced by incorporating parallel computing, as discussed in the previous chapter. We could
also take advantage of the fact that shifting the patient in a direction parallel to the beam axis
(i.e. changing the air gap) does not change the proton dose distribution by much, thereby
further reducing size of the search space.
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Figure 24: A graphical user interface for dose-based alignment with inputs for DVH-based
objectives.

Since anatomy change can affect the proton range from each individual beam
differently, a beam-specific isocenter shift may potentially further improve the dose delivered
to the patient. Additionally, individual field alignments may be applicable for multi-room
facilities where prolonged waiting times between beams may be routinely observed. Ideally,
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this beam-specific isocenter shift would take into account the total dose from every beam in
our optimization process. However, the search space is unacceptably large for a brute force
search. For example, calculating the optimal shift for linked beams for a 3-beam plan would
require 7293 or 387,420,498 combinations of beams. Even with all of the possible doses
precalculated for each beam separately, calculating the objective function for all
combinations of beams using our current methodology would take too long to be feasible for
real-time application. We performed an initial study looking at performing a multiple
isocenter shift using independent beam-specific dose optimization. We did this by looking at
each beam separately and finding the isocenter shift that optimizes the dose to the target and
the ipsilateral lung with the same parameters as our single isocenter dose-based optimization
weighted by the relative beam-weighting in the treatment plan. It is important to point out
that this multiple isocenter shift method makes sense only for proton delivery techniques in
which each field is separately optimized to deliver uniform dose to fully cover the target.
After this independent optimization, we looked at the resultant total dose delivered for each
beam with the obtained isocenter shifts. In this study, we did not demonstrate the significant
advantage of using the beam-specific isocenter shift method over the single-isocenter shift
method. The mean ipsilateral lung doses for the single- and multiple-isocenter shifts did not
significantly differ (p = 0.9464). The multiple-isocenter dose-based method resulted in mean
(max) ipsilateral lung doses that were lower by an average of 2.77% (11.0%) of the
prescribed dose (p = 0.0086) compared to 2.74% (11.3%) of the prescribed dose for singleisocenter (p = 0.0147). While these doses are not significantly different, we can see that there
is potential advantage to performing multiple-isocenter beam shifts to better optimize the
dose that is delivered to the patient.
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4.5.

Conclusion

We showed that because proton dose distribution changes with changes in anatomy in the
beam path, a pure geometry-based target alignment is potentially insufficient for patient
setup in proton therapy. On the other hand, we demonstrated that a dose-based patient setup
was an effective image guidance approach for proton therapy. This particular approach
improved target coverage and/or reduced dose to nearby normal tissue compared with the
traditional anatomy-based image guidance approach based on our analysis of the dose to the
ipsilateral lung. We proposed a unique approach to use a dose-based objective function to
guide patient setup (i.e. isocenter adjustment), which bridges the gap between traditional
image guided setup and the more complex adaptive radiotherapy. We showed that 7 of 15
plans did not meet the target coverage constraint when we used anatomy-based alignment.
After we applied dose-based isocenter alignment, all met the target coverage constraint. The
proposed dose-based alignment approach will also be useful as a trigger for adaptive
radiotherapy when the dose-based simple isocenter shift method becomes inadequate to
correct for more complicated dosimetric deviations in the treatment plan.
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CHAPTER 5: SPECIFIC AIM III - A FAST ONLINE RANGE-ADAPTIVE
TECHNIQUE TO CORRECT FOR RANGE VARIATIONS BASED ON CT
IMAGING

5.1.

Introduction

The potential for proton therapy to deliver improved dose distributions is well documented in
both planning studies and clinical outcome studies.15, 17, 109 However, a frequent concern with
proton and other particle therapy techniques is their sensitivity to range variations due to
anatomical changes over the course of treatment.31, 79, 94, 110-112 As discussed earlier, it is also
well-known that patient anatomy does not remain constant over the entire course of
treatment, with changes stemming from patient weight loss, tumor shrinkage, radiationinduced swelling, and inconsistent patient setup, to list a few common examples.36-39 Because
of the finite range of protons within the patient, any of these changes can potentially affect
the delivered dose to the patient, compromising the treatment by causing overdosing of
normal tissues or underdosing of the target. Therefore, adaptive strategies are commonly
used to correct these problems.95, 113, 114 Koay et al.95 found that as many as 20% of patients
in the proton therapy arm of a trial of radiation therapies for non-small-cell lung cancer
(NSCLC) required adaptive intervention at some point during the course of their treatment.
Additionally, they found that most of their adaptive corrections required only aperture,
compensator, or beam energy adjustments and did not require changes in beam angles or
number of beams.
However, an issue with adaptive replanning is that it requires a large amount of
resources and can take several days to implement. This can lead to a strain on resources
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within the department and forces patients and radiation oncologists to choose between using
an inadequate treatment plan or interrupting treatment while replanning is done. Therefore, a
method for quick adaptive replanning would be immensely beneficial. Implementation of
such a method would require a quick turnaround time for the entire process: treatment
assessment, reimaging for treatment planning, treatment planning itself, data transfer to the
delivery system, and all quality assurance measures to ensure safe delivery of the treatment.
In SSPT,8, 25, 115 the proton beams are delivered using electronically controlled scanning
magnets, beam energy, and beam intensity so no special patient-specific hardware is required
to be manufactured. Therefore, with SSPT we have the potential for adapting plans on the fly
by programmatically adjusting the beam energy and by adjusting the lateral scanning position
by changing the magnetic steering.
To begin to assess this potential, we explored a potential range-adaptive method for
quick adaptive planning based solely on the use of the original treatment plan and a new
treatment-time CT image of the patient. The objective of this method is to make minimal
modifications to the original treatment plan to simplify the adaptive process and reduce the
amount of quality assurance needed for a safety check. In addition, the use of CT imaging
allows for possible implementation into the process of image-guided patient setup and
evaluation. Here we report our findings on the successes and limitations of this range
adaptive method for single-field optimized (SFO) SSPT.

84

5.2.

Methods and Materials

5.2.1. Patient data set
Fourteen patients with NSCLC who were previously treated with passive scattering proton
therapy were selected for this study. These patients were a subset of patients who were
enrolled in a randomized clinical trial to compare proton therapy and photon intensitymodulated radiation therapy for lung cancer (NIH P01 CA021239-29A1). All of the patients
selected for the present study had received at least one adaptive intervention during the
course of treatment to mitigate potential dose delivery deviations caused by large changes in
their anatomy. In addition, these patients all had undergone weekly 4DCT imaging during the
course of treatment to monitor for such changes. The patients were treated in free breathing
conditions and were set up daily using orthogonal x-ray imaging. We elected to select lung
patients for this study in order to take advantage of their large anatomical changes during the
course of treatment. Again, no special motion management was used in our adaptive
planning. Table 9 shows some treatment and tumor characteristics of the patients we studied
in this aim.

5.2.2. Treatment Planning
For the patients selected, we generated SFO SSPT plans using our clinically commissioned
treatment planning system, Eclipse™ (version 8.9.08a, Varian Medical Systems, Inc., Palo
Alto, CA). All contours (including the target volumes and normal tissue structures), beam
angles, and beam weights were selected to be the same as those in the clinically approved
passive scattering proton therapy treatment plans used for our patients.

85

Table 9: Tumor and treatment characteristics for Specific Aim 3 study.

Abbreviations: Adeno = adenocarcinoma; SCC = squamous cell carcinoma; LCLC = large
cell lung carcinoma; RUL = right upper lobe; LUL = left upper lobe; RLL = right lower lobe;
LLL = left lower lobe

The treatment plans were created to meet clinical DVH based guidelines at our
institution (same as in Specific Aim II): PTV D99% ≥ 95% of the prescribed dose; total lung
volume receiving a dose of at least 20 Gy (V20Gy) ≤ 37%; total mean lung dose (MLD) ≤ 22
Gy; maximum spinal cord dose (Dmax) ≤ 45 Gy; and minimizing the esophageal V65Gy and
V55Gy and heart V60Gy and V40Gy. The prescription dose for all patients was 74 Gy to the target
in 37 fractions. For the target volumes, the GTVs at all phases from the 4DCT were
combined to create the internal gross tumor volume (iGTV). The ITV was generated by
uniformly expanding the iGTV by 8 mm, followed by manual editing by the physician. The
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PTV was then generated by applying a 5 mm uniform expansion of the ITV, with some edits
to avoid non-involved bone and superficial structures.
For treatment planning optimization, we optimized to the PTV as the target, but for
evaluation we looked at the ITV. Note that we did not include additional margins for range
uncertainty in our planning or evaluations33, 94, 116 because the purpose of this work was to
determine whether we can adjust beam parameters to match the original coverage to the
target after correcting for anatomy change. Therefore, we wished to isolate the effect of
anatomy change from treatment planning range uncertainties in this study. We did, however,
include a 1.0 cm margin based on the plan spot spacing to allow for the placement of a single
shell of spots outside of the target. This was done to allow freedom for the optimizer to
deliver uniform dose to the target. The average 4DCT image was used for plan optimization
and dose calculation.

5.2.3. Treatment-time image pre-processing
The average 4DCT from the last available weekly scan was used for evaluation of delivered
dose using the non-adaptive and adaptive plans. Deformable image registration was
performed using in-house software88, 89, 101, 102 in order to transfer the original contours of the
treatment target and normal tissues to the new treatment-day anatomy for assessment. Again,
image processing was also performed in order to digitally replace the couch on the CT scan
with the treatment couch, since the two differ.100
In order to recreate the patient’s treatment position, we performed image registration
to obtain the isocenter for the treatment-time CT. The alignment target was to the iGTV soft
tissue.
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5.2.4. Range calculation in CT imaging
As described in Section 1.8, the proton range to any point in a patient can be calculated by
integrating the relative stopping power of all tissues along the beam path in a CT image.
Information regarding the relative stopping power of tissues within the patient can be
estimated from CT imaging through previously measured calibration curves.68 Therefore, the
proton radiological range, or WEPL, to any voxel in the CT image can be calculated by
integrating the relative stopping power ratios along the line segment from the beam source to
the voxel of interest in the image.

5.2.5. Adaptive algorithm
With information about the new target anatomy on the treatment-time CT image, we can
calculate the new ranges for the proton beamlets that are needed in order to cover the new
target anatomy. If the new anatomy requires a smaller range than the original plan, then the
energies of the proton beamlets can be decreased in order to avoid unnecessarily overdosing
normal tissues distal to the target. Similarly, if a larger range is needed, then the energies of
the proton beamlets can be increased to ensure that the target is adequately covered. Our
current implementation of such changes are similar to those described by Zhang et al.,117 but
with additional correction factors to account for target morphology changes and proton beam
changes. Before range adaptation of the spot positions were performed on the new anatomy,
we calculated the difference between the range to the distal edge of the target on the planning
CT image and the actual range of the distal proton spots in the plan to obtain the excess spot
position range that was needed for each beamlet in the optimized proton plan to deliver a
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uniform dose to the target. This excess range distal to the target was added to the
corresponding beamlets in the range-adapted plans in order to cover the distal edge of the
target. The range-adaptive adjustments were then performed on a ray-by-ray basis (i.e. spots
with the same X and Y positions in the two-dimensional spot grid but with different energies)
uniformly in order to match the range to the distal edge of the new target. The spots were
then matched to available discrete energies from our synchrotron-based clinical proton beam.
Thereafter, any spots that ended up lying outside of the target proximally were removed. If
more spots were required to cover the proximal side of the target (e.g. the target volume
increased or the upstream density decreased), then additional spots were added to
accommodate the disparity. This process is similar to adjusting the beam parameters on a
daily basis to optimize a 2.5D modulation field as described by Lomax.118 An example of this
step in the process is shown on a pelvic phantom in Figure 25. We devised the original plan
to deliver a uniform dose to a circular target at the center of the phantom. After introducing a
bone-like material in the path of the beam, the delivered proton spots are pulled back
proximally due to the increased density of the material along the beam path. Therefore, we
can dial up the energies of the proton spots to account for this necessary change in range and
obtain a spot placement close to that of the original plan on the new anatomy.
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Figure 25: An example of the range-adaptation on a pelvic phantom. On the top row are the
spot positions that are needed to deliver a uniform dose to the circular target at the center of
the phantom. On the bottom row are the resultant dose distributions. The first column shows
the original plan with no range perturbations. The second column shows what happens to the
original plan when a bone-like material is introduced in the path of the beam. The third
column shows the resulting spot position and dose when the ranges of the spots are adjusted
to compensate for the change in anatomy.

As shown in Figure 26, a change in the energy of the beam with a fixed spot weight,
or monitor unit (MU), will result in a difference in dose that is delivered both at the peak
dose depth and at locations proximal to the peak dose because of changes in the energy
straggling and lateral scattering of the beam. Therefore, if we change the energy of an
individual spot, the MU for that spot will need to change as well in order to compensate for
the difference in dose delivered. In addition, any change in the MU for a given spot will
affect the dose that is delivered proximal to the spot, and therefore the MU for all spots
proximal to the adjusted spot will also need adjustment. Different methods for correcting the
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MU based on integral depth dose (IDD) and central axis depth dose (CAX) were explored in
order to directly correct for this effect after applying our range correction. The relative doses
for all energies less than each available clinical energy were included in a lookup table to
obtain adjustment factors needed (Figure 26). Therefore, the cumulative adjustment needed
for any proton spot along a ray could be calculated as needed.
The lateral coverage of the proton beam also had to be considered as we adapted the
original plans to match the patients’ new anatomy. As shown in Figure 27, proton beam
optimizers tend to favor increasing the spot weights to the peripheral spots in a proton plan in
order to achieve a uniform dose distribution and increase the sharpness of the penumbra.
Therefore peripheral spots cannot simply be removed if the target anatomy shrinks in the
lateral direction, or the target coverage will deteriorate. Similarly, if the target size grows in
the lateral direction, adding spots outside the peripheral spots will adversely increase dose to
the normal tissue outside of the target.
We selected correction factors to increase or decrease the peripheral spots depending
on changes in the target’s lateral size. The correction factor lookup table was generated based
on a phantom study in which we delivered a SFO SSPT plan to a cylindrical target uniform
water phantom. In this phantom study (Figure 28), we changed the target’s lateral size in
increments of 1 mm to ±10 mm to assess how target coverage responded to adjustments in
the peripheral spot weights, which we changed in increments of 1% to ±30%. Correction
factors for lateral changes were determined based on preserving target V99% ≥ 95%, while
ensuring hot spots were kept to a minimum (target V110% < 5%) (Figure 29). Figure 30 shows
the correction factors that were determined from the phantom study.
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Figure 26: Depth dose curves of all of the clinically available energies at our proton therapy
center and the relative doses for all spots proximal to the given energies. (Left panels)
Integral depth dose (IDD) and central axis depth dose (CAX) curves for all 94 available
clinical beam energies of our proton therapy system based on treatment planning system
calculations for individual spot doses of different energies with a fixed monitor unit (MU).
Note that for different energies, the deposited dose changes when delivering the same MU
and that any change to spot weights for those with higher energies will affect the dose
delivered along the entire path of the beam. (Right panels) Lookup table generation for
relative spot positions and intensity corrections for different energies for the IDD and CAX
methods based on relative locations of proximal spots. The spot correction locations needed
for beam energies of 201 MeV are highlighted in green.
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Figure 27: A graph showing the difference in the proton beam penumbra for a spot scanning
system between (a) a uniform proton fluence and (b) an “edge-enhanced” proton fluence. The
“edge-enhanced” proton fluence as represented by the summation of the individual proton
spot profiles with the protons on the periphery given more weight as shown in the figure.
Reprinted from E. Pedroni, United States Patent No. 7560715 (July 14, 2009 2009).
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Figure 28: Image of the phantom and contours that were used for generation of the lateral
size corrections lookup table. The red contour shows the original target and the yellow
contours show the target with increasing and decreasing lateral margins.
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Figure 29: Generation of lookup table for lateral size corrections. Each curve shows the
target coverage (V99%) for different lateral size changes of the target volume. Scalar
adjustment factors between 0.75 and 1.3 in increments of 0.01 were applied to the peripheral
spot weights to compensate for lateral size changes.

Figure 30: The resultant correction factors for lateral size changes based on target coverage
(target V99% ≥ 95%) and target hot spot (target V110% < 5%) criteria.
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The plan parameters, including beam configurations, spot positions, and spot
energies, from the original treatment plan were registered to the treatment-time image to
obtain the verification (non-adaptive) dose distribution. This verification plan, along with the
original plan parameters, was exported to be modified based on our range-adaptive
algorithm. The plan parameters and the treatment-time CT were read into Matlab (The
MathWorks Inc., Natick, MA) using the CERR104 file format structure, and the plan was
adapted with the various techniques for energy correction and with and without lateral
corrections as described earlier. We looked at adaptations with:
1) range adaptation only (Range Adapt),
2) range adaptation with lateral corrections only (Adapt w/ Lat Corr),
3) range adaptation with CAX-based energy corrections only (Adapt w/ CAX Corr),
4) range adaptation with both lateral and CAX-based energy corrections (Adapt w/
Lat Corr and CAX Corr),
5) range adaptation with IDD-based energy corrections only (Adapt w/ IDD Corr),
and
6) range adaptation with both lateral and IDD-based energy corrections (Adapt w/ Lat
Corr and IDD Corr).

5.2.6. Adaptive Plan Evaluation
The resultant adaptive plans were evaluated against the non-adaptive verification plans. We
looked at various DVH parameters for the target and normal tissues, including the ITV
coverage (V95%), ITV hot spots (V110%), spinal cord maximum dose (Dmax), total and
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contralateral lung dose (V20Gy), heart dose (V40Gy), and esophagus dose (V55Gy). Differences
between these values in the adaptive and non-adaptive plans were then subjected to statistical
analysis.
We compared the various adaptive techniques to each other by using a repeatedmeasures analysis of variance of the differences in DVH parameters between each of the
adaptive and non-adaptive plans. To determine whether there was a statistically significant
improvement for each of the adaptive plans compared to the non-adaptive plans, we
performed a 2-tailed paired t test with a 95% confidence interval. We performed our
statistical analysis using GraphPad Prism (version 5.00 for Windows; GraphPad Software,
San Diego, CA), and a p-value less than 0.025 and 0.010 was considered statistically
significant for the target and normal tissues, respectively, based on a Bonferonni correction
to correct for the multiple comparisons we are making in this analysis.

5.3.

Results

On average, all of the adaptive plans reduced the dose to normal tissues when compared to
the non-adaptive plans. However, improvements in the target coverage varied greatly and, in
general, resulted in hot spots that were not exhibited in the non-adaptive plans.
Figure 31 shows columnar scatter plots of the differences in normal tissue DVH
statistics between the non-adaptive and each adaptive plan and the means and standard
deviations in those statistics for the 14 patients. The paired mean differences for these
comparisons along with the p-values for the paired t tests are shown in Table 10. The paired
mean differences showed a decrease in the normal tissue dose for the population for all of the
adaptive techniques used. This difference was statistically significant for all of the adaptive
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techniques without lateral correction for the spinal cord Dmax and total lung V20Gy, and for all
of the adaptive techniques for the contralateral lung V20Gy. They were not statistically
significant for the heart V40Gy and were mixed for the esophagus V55Gy. For all patients
except one (patient 5), there was an improvement in normal tissue dose sparing for a majority
of the organs evaluated. Patient 5 had an increase in normal tissue dose for all organs.
However, this patient also had the largest change in tumor size and the largest improvement
in target coverage. The repeated-measures analysis of variance indicated that there were
statistically significant differences between the different adaptive techniques for the total
lung doses, but not for the other normal tissues evaluated.
Figure 32 shows columnar scatter plots of the absolute values of and differences
between the adaptive and non-adaptive plans for the ITV target coverage (V95%) and hot
spots (V110%) for all the patients, along with means and standard deviations. On average, all
adaptive methods except for that with both lateral and IDD energy corrections showed a
reduction in target coverage. Furthermore, in almost all cases, the adaptive techniques
resulted in an increase in hot spots compared to the non-adaptive plans, with many showing
substantial increases of over 10% in V110%; the mean increase in target hot spots for all the
plans was statistically significant. The repeated-measures analysis of variance indicated that
there were statistically significant differences in the population means between the different
techniques for both target coverage and target hot spots. The addition of lateral corrections to
all techniques resulted in improved target coverage but worse hot spots. The CAX
corrections were best at reducing hot spots but also resulted in reductions in target coverage.
The IDD corrections tended on the whole to increase the dose to the target, resulting in better
target coverage but worse hot spots.
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Table 10: Target and normal tissue DVH metric comparisons for all of the adaptive techniques
relative to the non-adaptive plans
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Figure 31: Columnar scatter plots of the normal tissue DVH metric differences between the
adaptive and non-adaptive plans for all 14 patients and for each of the six adaptive correction
methods.
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Figure 32: Columnar scatter plots for the ITV DVH metrics (top) and DVH metric
differences between the adaptive and non-adaptive plans (bottom) for all 14 patients and for
each of the six different adaptive correction methods.

5.4.

Discussion

Taken together, our data show that adaptive planning by making direct adjustments to the
original treatment beams for SFO SSPT is difficult to achieve without creating undesirable
dosimetric effects that may compromise outcomes. However, our adaptive techniques all
performed well in reducing the normal tissue dose. Since they all rely principally on
adjusting the range of the delivered proton spots to match the ranges calculated on the new
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target anatomy, normal tissues that lie distal to the target anatomy stand to benefit most. Such
benefits are apparent when looking at the spinal cord and contralateral lung doses. Both of
these structures saw relatively large decreases in dose after applying our adaptive techniques
since the clinical beam angles tended to avoid going through these structures to treat the
target; as is common, though, the plans often necessitated aiming at least one beam toward or
near these structures in order to viably treat the target. In the case of lung cancers, the tumor
response typically results in shrinkage of the soft tissue target, exposing more lung tissue in
the path of the beam and resulting in an overshooting into the normal tissue distal to the
target. The range adaptive techniques described here allow for these problems to be
mitigated.
While the esophagus and heart saw noticeable decreases in dose when adaptive
replanning was done, the differences between the adaptive and non-adaptive plans were
generally not statistically significant, likely because of the locations of these structures. That
is, the esophagus and heart tended to be close to the target for most of our cases and therefore
already contained areas receiving high dose. This was especially apparent for the heart, as the
heart V40Gy varied considerably between the different adaptive techniques.
While these adaptive techniques showed some success with normal tissue sparing in
our cases, the resultant dose to the new target anatomy varied and resulted in increased
heterogeneity and reduced target coverage. Efforts to correct these problems by making
fundamental adjustments to the proton spot intensities based on calculated depth dose curves
and lateral size changes were unsuccessful in correcting these issues. The main objective of
this work was to come up with an adaptive methodology that could potentially be applied as
an online process, with minimal modifications to the original optimized plan. However, our
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results show that changes in patient anatomy for cases that require adaptive intervention are
substantial enough that the original optimized conditions break down and that a clinically
acceptable plan cannot be recovered with the simple modifications proposed here. We
believe some sort of dose-based reoptimization of the plan is likely needed to acquire an
acceptable adaptive plan; future work in adaptive planning therefore should be focused on
fast reoptimization techniques.
In response to the results, we wished to see if there was any way to predict whether a
given patient would be a good candidate for applying this adaptive technique. To do this, we
evaluated whether there was any correlation between the magnitude of anatomy change to
the change in target coverage and target hot spots for the different adaptive techniques. For
the magnitude of anatomy change we evaluated both the iGTV volume change and the
difference in weighted average of the maximum WEPL range for the adaptive plans
compared to the non-adapted plans. Unfortunately, we found no statistically significant
correlations between these variables when evaluating target coverage. The degree of target
hot spots showed moderate statistically significant correlation to iGTV volume change for
both of the IDD correction methods (R-square of 0.6253 and 0.5420 for the Adapt w/ IDD
Corr and Adapt w/ Lat Corr and IDD Corr methods, respectively) and weak correlation to the
average maximum WEPL difference for the Adapt w/ IDD Corr method (R-square of
0.2723). However, due to the lack of correlation for the target coverage criteria, this
correlation is not clinically meaningful.
We chose again to examine only lung cancer patients for this study because the
impacts of anatomical change in proton therapy are potentially the greatest in these cases due
to the low-density tissues involved and the typically large tumor responses. Therefore, these
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cases stand to gain the most benefit from adaptive planning in proton therapy. Additionally,
this allowed us to include a wide range of tumor size changes in our study to test our adaptive
techniques. In prostate treatments, anatomical changes have been shown to have minimal
effects if appropriate measures were taken to ensure proper planning and accurate patient
setup , and so our findings are not particularly applicable in that setting.110, 111, 119, 120
Conversely, while such variations have demonstrated large effects in head and neck proton
therapy,121 the use of SFO SSPT for those cancers is limited due to the close proximity of
critical normal tissue structures and the complex target structures in most of these cases, and
multi-field optimized or full intensity-modulated proton therapy is a more promising method.
Thus, while the adaptive technique described here can be in general applied to any treatment
site with SFO SSPT planning, specific advantages and disadvantages need to be assessed,
especially with the problems seen with target coverage and hot spots.
While in-room volumetric imaging is not currently available in most proton facilities,
CT scanners in proton therapy vaults have been planned for many future centers. Integrated
x-ray or possibly proton cone-beam CT scanners can potentially be used as well.122 While
accurate dose calculations in proton therapy have not been sufficiently demonstrated using
cone-beam CT imaging,123-125 work on CT number correction has shown promise for
potential future use in proton therapy. Therefore, in-room volumetric imaging for proton
therapy and their effective use for proton image-guidance and adaptive therapy is likely to be
of forthcoming clinical importance.
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5.5.

Conclusion

Since proton beams are very sensitive to anatomical changes in the target and along the beam
path, online adaptive therapy may be essential to ensure acceptable delivery of the proton
therapy. This work is important because it identifies key successes and limitations of
applying various simple adaptive methodologies to correct for interfractional anatomic
changes in spot scanning proton therapy. We determined that normal tissue doses can be
minimized with these methods but that the dose to the target is not adequately corrected for
and that large changes will likely require some form of reoptimization for adaptive planning.
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CHAPTER 6: DISCUSSION AND CONCLUSION OF DISSERTATION

6.1.

Testing of hypotheses

At the beginning of the dissertation, we hypothesized that we could use information from CT
imaging to verify and assess the dose delivered on the day of treatment, and to make
corrections as necessary to patient setup and to adapt the treatment in order to maintain target
coverage and reduce normal tissue dose. To test this hypothesis, we devised the three specific
aims presented in the preceding chapters.

6.1.1. Overall hypothesis
The overall hypothesis was that a radiological pathlength calculation algorithm based on CT
imaging could be used for online proton beam treatment day verification and isocenter
adjustment, and online adaptive range adjustment technique based on pathlength correction
in order to maintain target coverage and reduce normal tissue dose. We were able to develop
and test the techniques proposed at the beginning of this dissertation and demonstrate their
relative successes and limitations.

6.1.2. Specific Aim I
The goal of this aim was to develop an online proton dose verification tool based on daily CT
imaging to assess the effect of anatomy change on the proton beam and validate its ability to
evaluate target coverage and dose distribution. The working hypothesis was that the online
range corrected dose approximation tool could estimate the dose distribution based on the
new patient anatomy to an accuracy given by a gamma index (3%/3mm) > 85% when
106

compared to full dose recalculation. We were able to successfully develop a proton dose
verification tool that can feasibly be used as an online process utilizing treatment-time CT
imaging. We demonstrated that a range-corrected proton dose approximation method can be
used to estimate the delivered dose to a patient to better than 93% and 84% for setup position
changes and severe anatomy changes, respectively, when looking at the 3D gamma analysis
passing rate with a 3% dose difference and 3 mm distance-to-agreement criteria. Moreover,
the DVHs agreed very well with treatment planning system calculations with an average of
RMS (maximum deviation) of 0.5% (1.5%) for setup position changes and 0.6% (2.7%) for
weekly anatomic change. The goal of meeting an 85% passing rate for the 3D gamma
analysis was met for all of the cases evaluated in this study except for the worst case head
and neck instance, in which we saw a Gamma Index passing rate of 84%. Therefore, while
our results strictly require us to reject the hypothesis, the method presented is still useful as a
tool for dose assessment. The cases tested in this study were intentionally extreme examples
of anatomical changes that have been seen at our institution. In addition, the beam angles that
were selected for this evaluation were chosen to exaggerate the effect of the anatomical
changes on the proton beam. The dose approximation did well under these circumstances and
can be very useful tool to catch major errors in dose delivery. Moreover, when looking at the
DVH, our technique shows good agreement to full dose calculation. Therefore, use of this
technique with either dose distribution maps or DVH-based metrics can potentially be an
indicator for compromised treatments, informing further decisions for possible corrective
action. Additionally, the results looking at the accuracy of the dose approximation algorithm
on setup variations showed very good agreement, making it useful for applications for robust
analysis, or dose-based patient setup evaluation as is used in Specific Aim II.
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6.1.3. Specific Aim II
The goal of this aim was to devise a novel patient setup correction method for proton therapy
based on dosimetric indices and to assess its ability to maintain target coverage and improve
normal tissue sparing. The working hypothesis was that this dosimetric alignment method
based would result in a statistically significant reduction in normal tissue dose compared to
anatomical alignment. Here, we used the tools developed in Specific Aim I to calculate the
dose for numerous patient setup positions within a defined search space to obtain the optimal
patient setup position. This is a basic adaptive correction principle that is commonly used in
the clinic with IGRT patient localization, but current practice is limited to looking at
anatomy-based alignment only. By using dose information for patient setup, we are not only
able to obtain the best setup position for the patient, but we can also use this to inform us of
the need for a more comprehensive adaptive correction if the treatment is compromised for
all possible isocenter shifts.
Testing this technique on our cohort of patients, we found that we were able to recover
our target coverage to meet clinical constraints in all of the cases where the anatomy-based
alignment did not. In addition, we were able to statistically significantly improve the normal
tissue sparing in cases where both anatomy-based and dose-based alignment methods met the
target constraint. We demonstrated its use in lung patients, but the application can easily be
extended to any treatment site. As discussed, clinical implementation will require decisions
to be made regarding trade-offs of optimizing to different normal tissues. This decision can
be site or patient specific. If clinical requirements are not met by this process then other
adaptive strategies such as that tested in Specific Aim III can be considered.
108

6.1.4. Specific Aim III
The goal of this aim was to develop an online range compensation beam adjustment
technique to correct for range variations due to anatomical changes while preserving target
coverage in SFO spot scanning proton therapy. The working hypothesis was that this online
range-adaptive technique based on pathlength correction could maintain the original target
dose coverage (V95%) to within 5% while significantly reducing normal tissue dose
compared to non-adaptive treatments. We developed an adaptive technique that takes
advantage of the ability to adjust the proton beam on the fly for a spot scanning system. The
corrections included in the process are meant to be applicable without any need for iterative
dose-based reoptimization. It is important to note here that the dose approximation algorithm
from Specific Aim I would not be applicable to estimate the dose after applying this adaptive
strategy since the beam parameters are different from the original planned parameters.
Therefore, the assumptions of our dose approximation algorithm break down and the dose
cannot be estimated by the remapping process.
We found that our adaptive techniques were able to reduce the dose to normal tissues
but were unsuccessful at preserving target coverage and uniformity. While the results for
Specific Aim III were negative, we were able to demonstrate relative success in reducing
normal tissue dose. The problem with making such proposed changes to the proton beams is
that the original optimization conditions are disrupted and direct changes to accommodate
changes in the proton delivery are not enough. Furthermore, we were unable to determine a
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priori which patients may benefit from such an adaptive technique based on anatomical
changes.
Future studies looking at further exploring other correction factors for adaptive
planning may allow for improvements to target uniformity. For example, one factor that was
not taken into account in this study was the change in spot size due to energy changes. In
order to preserve the original optimization conditions, we elected to maintain the same spot
spacing as was needed in the original treatment plan. However, the spot spacing may
necessarily be changed as well in order to address the differences in energies for spot
delivery. Exploration of such modifications may allow for a more homogenous dose to be
delivered to the target. A different approach may be to utilize the updated dose information
after performing our initial adaptive adjustments to determine additional modifications that
can be made to manage target coverage and perhaps even further reduce normal tissue dose.
This approach moves toward performing a full reoptimization of the plan but can possibly be
performed using just a few iterations with the initial adaptive adjustments serving as a
starting point. If this approach is utilized, the time savings and the quality of the adaptive
plan compared to a full-fledged adaptive replan would need to be assessed to determine
clinical applicability. We hope that the adaptive techniques assessed in our study will be
informative of future efforts to implement quick adaptive planning for proton therapy.

6.2.

Future work

There is much work that needs to be done in order to implement the work presented in this
publication in the clinic. While the analysis may be specific to our clinic and mostly tested on
lung patients, the methods as presented are general processes that are non-specific with
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regards to institutional clinical guidelines, treatment site, and vendor, and can be widely
implemented to specific clinical needs. However, all of the work presented here is
developmental and full application of them will require streamlining the processes and
implementation into a clinically viable workflow. This requires many steps, including system
integration, workflow process, clinical training, and validation for the specific clinical
applications of interest. The quality assurance that is needed for such techniques was not a
focus of the project and is left as an open question. Quality assurance needs will be very
specific to the application and the specific system in place at an institution and careful
consideration is needed in implementing any aspects of these processes.
An additional issue that needs to be considered is the utilization of other developed
processes that are needed within this adaptive procedure. Our studies examined the use of
repeat CT imaging for patients. Therefore, in order to implement these processes, the ability
to image the patient in the treatment room is necessary. On top of this, automatic
segmentation is needed in order to streamline the process and reduce the time needed for data
preparation. Solutions for data management and system integration of these components will
be an essential part of implementing these processes.
Due to the complexity of proton therapy and the dynamic nature of patient anatomy
and physiology, verification of proper dose delivery is an important endeavor. An individual
patient’s response to treatment will be unique and difficult to predict. Additionally, the
increasing value and trend toward personalized medicine is indicative of the desire for
adaptive radiation therapy. We hope that the methods and results presented in this work will
be of benefit toward this goal to deliver the best care to radiation therapy patients.
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